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The protein kinase Mammalian Target of Rapamycin (mTOR) is a master 
controller of cell growth and proliferation due to its ability to integrate growth 
signals and regulate translation through 4E-BP1 and p70-S6K.  We developed 
four phCMV2-HA-tagged plasmids to overexpress TOR in mammalian cells: Wild 
Type, D2357E (Kinase Dead), R2109A (PA Binding Deficient) and, S2035T 
(Rapamycin Resistant) each verified by restriction enzyme digestion and direct 
sequencing.  Plasmid DNA was overexpressed in COS-7 cells and the 289 kDa 
protein detected in Western blots developed with anti-HA and anti-mTOR 
antibodies.  Kinase activity of the overexpressed protein was detected by in vitro 
phosphorylation of 4E-BP1 and S6K.  QRT-PCR detected a 200 fold increase in 
mTOR gene expression over mock transfected cells, but found no change in 
PLD2 gene expression.  Immunoflourescence microscopy indicated that mTOR 
is perinuclear, concentrated in endosomal formations.  This study provides the 
molecular biology tools for continuing investigation into the crosstalk between 
mTOR, S6K, PLD1 and PLD2.  
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I.  LITERATURE REVIEW 
Discovery of mTOR 
During a 1970’s expedition to Easter Island, off the coast of Chile, South 
America, researchers discovered a strong antifungal metabolite produced by the soil 
bacteria Streptomyces hygroscopicus1.  The newly discovered macrolytic lactone was 
named rapamycin after the island where it was found, which is called Rapa Nui in the 
local language2.  Further study revealed immunosuppressive properties and the ability 
to inhibit mammalian cell growth while the macrolydes mechanism of action 
remained a mystery.  The addition of rapamycin to cell cultures results in G1 arrest in 
a variety of cell types3.  In 1980’s the National Cancer Institute screening program 
demonstrated the anti-tumor activity of rapamycin4.  These findings caused a flurry of 
research aimed at identifying the biochemical actions of rapamycin5.  By 1991 the 
extraordinarily specific target of rampamycin was identified though mutations 
TORC1 and TORC2, which confer resistance to rapamycin, and aptly named Target 
of rapamycin (TOR)6.   
Advances in biochemistry lead to the cloning of the “mammalian target of 
rapamycin” (mTOR), also known in the literature as “FK506-binding protein” 
(FKBP12), “rapamycin-associated protein” (FRAP), “rapamycin and FKBP12 target” 
(RAFT1), “rapamycin target” (RAPT1), or “Sirolimus effector protein” (SEP) 7.  For 
the purposes of this thesis, we will use the first nomenclature.  Every eukaryotic 
genome examined to date contains a mTOR gene8.  The TOR protein is highly 
conserved from yeast to man, sharing about a 95% homology at the amino acid level, 
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suggesting that it plays a vital role in cellular function9.  Genetically mTOR maps to 
the human chromosome 1p36.27.   
 
Cellular Importance of  mTOR 
mTOR is known to sense mitogenic stimuli, extra cellular nutrient levels10 and 
ATP11.  It also regulates cell functions including actin reorganization of the 
cytoskeleton,12 cell growth and proliferation,13 cell survival,14 transcription, 
translation initiation,15 mRNA turnover, protein stability,12 and repression of 
autophagocytosis (Figure 1).  Dysregulation of the mTOR signaling pathway16 is 
common in cancerous tumors including lung, bladder, renal, ovary, breast, prostate, 
gastric, pancreatic, and head and neck carcinomas17.  Dysregulation of the mTOR 
pathway has also been observed in lymphomas, melanoma, glioma and several other 
brain diseases18.  Unusually high mTORC1 activity is suspected as an underlying 
cause of these cancers19.  
 mTOR has been shown to be essential in development of mouse embryos, 
causing severe birth defects to mouse knockout mutants20.  Studies in Drosophila 
melanogaster and Caenorhabditis elegans have identified TOR as essential in 
embryonic development as well21.  Disruptions of the mTOR gene in mice result in 
embryonic lethality with severe telencephalon malformation, termed the “flat-top” 
phenotype.  Embryonic tissues requiring a rapid increase in cell proliferation, such as 
the telencephalon, limb buds and ventral body walls were malformed in the mTOR 
mutant genotype.  This finding seems to implicate mTOR in sensing mitogenic 
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mTOR plays a vital role in signaling cell growth, proliferation and survival.  The 
signaling network consists of two major branches, TORC1 and TORC2.  
TORC1 responds to growth factors including insulin and insulin-like growth 
factors and controls several pathways that determine the mass of the cell.  
The TORC1 acts largely through the control of the PI3K pathway, 
phosphorylating downstream targets, S6K and 4E-BP1 to control protein 
synthesis.  The TORC2 pathway is less well understood but has been 
implicated in cell survival and proliferation as well as control of the actin 
cytoskeleton, effectively regulating the shape of the cell. Main pathways are in 
black, with feedback loops depicted in red.  Arrows indicate activation of the 
downstream molecule, while inhibition of the downstream molecule is 
indicated with a stopped line.  Pathways which are yet unclear are indicated 
by dashed lines and question marks.  Direct phosphorlyation is indicated with 
the letter ‘p’ in a red circle. Figure adapted from Guertin, 2005.
mTOR Pathways
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difference in cell size in the mTOR mutant mice compared to a wild type mouse20.  
This finding seemingly does not agree with  previous reports that Drosophilia TOR 
mutants had a smaller average cell size than their wild type counterpart22. 
Characteristics of the “flat-top” phenotype include a failure to upregulate 
neuronal formation in the forebrain and inability to maintain gene expression in the 
prechordal region of the forebrain neuroectoderm20.  “Flat-top” mouse embryos die at 
12.5 days post coitus.  The same lab showed no survival differences in TOR mutated 
embryo’s versus wild type TOR embryo’s treated with rapamycin21.  After injecting 
rapamycin into wild type pregnant mice and observing effects similar to those in 
mTOR mutant mice they were able to assert that the malformed embryos were due to 
a disrupted mTOR pathway.  This experiment reinforced the tetrogenic effects of 
rapamycin and demands its further study as an anticancer drug16.   
 
mTOR Structure 
mTOR is a 289 kDa protein Serine/Threonine kinase which belongs to a 
family of phosphatidylinositol kinase-related kinases (PIKK)23.  After TOR mutants 
TOR1-1 and TOR2-1were identified24 a group of high molecular weight kinases 
including TOR, were identified that resembled the phosphoinositide 3-kinase 
family(PI3K).  This new family which shared sequence homology and were found in 
all eukaryotic cells was given the name phosphoinositide 3-kinase related kinases 
(PIKK’s)25.  There are several subfamilies of PIKK’s  including TOR subfamily, 
Atazia telangiectasia mutant,24 the ATM gene product and the DNA-dependent 
protein kinase.  PIKK’s are usually involved in functions critical to cell survival and 
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often regulate cellular responses to DNA damage, repair and recombination.  PIKK’s 
are also known to regulate cell cycle progression and cell checkpoints26.   
mTOR contains several conserved DNA sequences (Figure 2)27.  It contains a 
C-terminal kinase domain similar to protein and lipid kinases that is critical for the 
function of this family of kinases28.  mTOR also contains a unique domain at the 
extreme C-terminus end that are not seen in PI3 and PI4 Kinases20.   
The first 1200 amino acids of the mTOR sequence make up approximately 20 
tandemly repeated motifs composed of Huntington, elongation factor 3, the A subunit 
of protein phosphatase 2A (PP2A), and TOR 1p (HEAT domains).  The motif 
consists of patterns of approximately 40 amino acids in 3 repeating sequences, each 
containing the pattern of the hydrophobic; proline, aspartic acid, and arganine 
residues7.  The HEAT domains modulate protein to protein interactions through an 
extended superhelical structure, but their exact function is yet unknown12.   
Carboxy-terminal to the HEAT domains is the short segment of amino acids, 
termed the FAT domain, unique to PI3K’s.  Found between amino acids 1382-1982 
the FAT domain is always paired with the FATC domain at the extreme carboxy 
terminus of mTOR29.  The FATC domain gains its name from its components 
including: rapamycin-associated protein (FRAP), ataxia telangiectasia mutated 
(ATM), and transformation/transcription domain-associated protein (TRAAP), and its 
position at the carboxy-terminus.  While the FATC domain is unique to mTOR, 
researchers have suggested that the presence of the FAT and FATC domains serve to 













FIGURE 2:  
A schematic representation of the structure of the mTOR protein.  The 
first 1200 amino acids are patterns of approximately 40 amino acids in 3 
repeating sequences.  This domain modulates protein to protein 
interactions.  The FAT domain is a 600 amino acid sequence that 
modulate the function of the kinase domain.  Conservation of this domain 
is critical to mTOR kinase activity.  The FRB domain is the location of the 
binding site for which PA and FKBP12 compete.  The kinase domain is 
critical for cell cycle progression as mutations in this site lead to G1 cell 
cycle arrest.  This domain is also responsible for phosphorylation of 
downstream components of the mTOR pathway.  The FATC domain is 




critical as even the smallest change in amino acid sequence can cause mTOR to lose 
its kinase activity.   
Carboxy-terminal to the FAT domain is the FKBP-12-rapamycin binding 
(FRB) domain, which binds the FKBP-12-rapamycin dimer. Mapped from 2025 to 
301430, mutations in the FRB domain can confer rapamycin resistance to mTOR and 
have been exploited to allow a deeper understanding of the pathways with which 
mTOR is involved.  The FRB domain also plays a role in the upstream regulation of 
mTOR.  Studies have shown that FKBP1231, which is known to bind the FRB 
domain, was competitive with phosphatidic acid (PA) for that site.  The FRB domain 
contains a serine residue Ser2035 which is critically involved with the binding of the 
FRB region and the FKBP12-rapamycin complex.  Mutations at this residue with any 
other amino acid containing a larger side chain than serine prevent the proper tertiary 
complex formation32.   
The mTOR kinase domain is carboxy-terminal to the FRB domain.  The 
protein kinase domain resembles the catalytic domain of PI3K’s and holds an affinity 
for serine and threonine residues33.  The kinase domain in mTOR is essential for cell 
cycle progression that mTOR mediates.  Mutations in the kinase domain lead to G1 
cell cycle arrest34.  This domain is also required for the phosphorylation of 
downstream components including S6 Kinase and 4E-BP1 and is interchangeable 
within the PI3K family35. mTOR does not have any known lipid kinase activity36, 
although it does autophosphorylate37.   
mTOR is also thought to play a role in nuclear shuttling, which may have 
some regulatory effect on the downstream molecules, S6K and 4E-BP1.  mTOR is 
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considered cytoplasmic, generally localized to intracellular membranes38.  There is no 
known reason for mTOR’s localization to intracellular membranes, however.  Chen’s 
lab has also shown data which suggests that the continuous movement of mTOR from 
the cytoplasm to nucleus has implications in S6 Kinase activation and 
phosphorylation39.  Although mTOR has no conventional nuclear export or import 
signal, it is possible that it contains a novel transport sequence enabling it to move in 
and out of the nucleus40.  The lack of a clear nuclear localization sequence is not 
uncommon in the ATM-related kinase family though, and may explain the apparent 
lack of sequence.  Another proposed hypothesis is that mTOR translocates only after 
associating with an unknown transport vehicle containing a standard nuclear shuttling 
protein39.  Ongoing research in different labs is aimed at confirming or disproving 
mTOR’s need for such a shuttling vehicle.   
Chen’s lab performed a number of experiements to determine the effect of 
mTOR shuttling.  Using leptomycin B (LMB), a specific inhibitor of the nuclear 
export receptor Crm1, the lab showed that the mTOR pathway was significantly 
inhibited in the presence of LMB39.  LMB treatment led to an inhibition of 4E-BP1 
phosphorylation and S6K activity.  In other experiments with S6K2, Chen’s lab 
concluded that: “It is thus likely that a balanced distribution of mTOR between the 
cytoplasm and nucleus, or an optimal shuttling rate of mTOR, may be essential for 
the maximal activation of downstream signaling41.”   
 
TORC1 and TORC2 
mTOR exists as two different multiprotein complexes within the cell42 (Figure 
3).  TOR complex 1 (TORC1) is composed of mLST8/GβL (mLST8 is also called G  
Rapamycin
FIGURE 3:  



































protein β-subunit-like protein) and Raptor (regulatory-associated protein of mTOR) 
and shows rapamycin sensitivity.  To date, the function of mLST8/GβL is unknown, 
although it may serve as an activator molecule43.  TORC1 controls many of the 
known pathways of the mTOR complex including phosphorylation of S6K1 and 4E-
BP1.  TORC1 is also responsible for transcription and translation initiation, thereby 
controlling the growth and proliferation of the cell44.  TORC2 is composed of 
MLST8/GBL and RICTOR-PROTOR45 (rapamycin-insensitive companion of mTOR 
and protein observed with RICTOR) complex, but shows no rapamycin sensitivity42.  
TORC2 is responsible for actin reorganization within the cell as well as 
phosphorylation of AKT at S47344.   
TORC1 and TORC2 respond differently to rapamycin.  TORC1, complexed 
with GBL and raptor proteins, show sensitivity to rapamycin.  Rapamycin and its 
receptor protein FKBP12 directly bind to and inhibit mTOR at the FRB domain. 
Although the mechanism is poorly understood46, recent studies suggest that the 
rapamycin/FKBP12 complex competes with the activator molecule PA for mTOR 
binding sites.  By interfering with the mTOR pathway, the effected cell is not able to 
proceed into the G1 phase of the cell cycle thereby unable to synthesize protein.   
 
Upstream Regulators of  mTOR  
There are several known upstream regulators of mTOR.  It is known that 
nutrient depravation or starvation conditions inhibit pathways that require mTOR47, 
while insulin, insulin like receptors, and nutrients such as amino acids or glucose 
upregulate mTOR48.  Protein synthesis is one of the most energy consuming tasks the 
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cell undertakes; therefore, it is easy to see why the cell strictly regulates these 
processes.  Individual cells must constantly assess mitogenic and nutritional signals 
around them and determine if enough raw materials exist for growth or 
proliferation49.  DNA and protein synthesis leading to an increase in individual cell 
size defines growth.  An increase in the number of cells in a population is termed 
proliferation50.   
Eukaryotic cells have complex, and not yet fully understood mechanisms that 
regulate protein synthesis and breakdown.  When cells sense a lack of raw materials 
including amino acids, oxygen, or growth factors cellular processes begin which 
prevent growth or proliferation51.  In times of need, the cell may even catabolize 
translational machinery for the raw materials in order to maintain homeostasis.  In a 
severe crisis, such as a lack of nutrients, cells initiate apoptotic pathways that 
eventually lead to the cells demise.  In times of abundance however, TOR functions 
to upregulate translation, cell growth, and actin reorganization.   
 
PI3K Pathway 
Currently the best understood mTOR activation pathway is through PI3-
Kinase (Figure 1).  In this pathway, mTOR is activated through various extracellular 
growth factors including Insulin and Insulin-like growth factor-1 (IGF-1)52.  Insulin 
and IGF-1 signal through integrins and chemokines through G-protein coupled 
receptors to the Insulin Receptor Substrate (IRS) in the plasma membrane of the cell.  
IRS then recruits PI3-Kinase to the cell membrane49. The newly recruited PI3-Kinase 
binds to phosphatidylinositol-4,5-phosphate (PIP2) in the cell membrane and converts 
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it to Phosphatidylinositol-3,4,5-phosphate (PIP3), a cell survival signal53.  PIP3 
recruits PDK1 and Protein Kinase B (Akt) to the membrane, binding the pleckstrin 
homology (PH) domain of Akt.  This causes PIP3 to dimerize, exposing its active 
catalytic site54.  PIP3 activates PDK1, which in turn phosphorylates and activates 
AKT49.   
 
AKT  
AKT is of particular interest because of its important role in apoptosis 
inhibition.  Phosphorylated AKT promotes cell proliferation through mTOR while 
inhibiting phosphorylation and activation of proteins such as the pro-apoptotic Bad 
protein55.  Tumor suppressor genes phosphatase and tensin homolog  (PTEN) and 
inositol polyphosphate-5-phosphatase D (SHIP) inhibit the phosphorylation of AKT 
by PI3K in a regulatory mechanism that prevents overgrowth56.  However in some 
cancers, PTEN is found to be mutated and the lipid phosphatase that inhibits the PI3-
kinase activity is not functional57.  This dysregulated pathway then can not prevent 
the overexpression of cancerous cells, allowing cell proliferation regardless of 
nutrient status.  Cancers with apoptotic resistant cells are commonly linked to PTEN 
mutations7.  AKT may also directly phosphorylate mTOR or act as an inhibitor of 
Tuberous Sclerosis Proteins 1 and 2 (TSC1 and TSC2) by phosphorylation of TSC258.   
 
Tuberous Sclerosis Complex (TSC1 and TSC2)  
Distal to AKT in the activation pathway of mTOR is the Tuberous Sclerosis 
Complex.  The TSC1/TSC2 complex is composed of the proteins hamartin (TSC1) 
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and tuberin (TSC2) which bind to mTOR in vivo, and also acts as a GTPase-
activating protein of Rheb.  TSC2 is an inhibitor of mTOR through Rheb, but when 
TSC2 is phosphorylated by AKT, its inhibitory effects are downregulated7.  The 
precise mechanism through which the TSC1/TSC2 complex is inhibited is yet 
unclear, but some reports suggest it is through the dissociation of the TSC complex59.  
When the PI3K pathway looses the inhibitory effects of the TSC1/TSC2 complex, the 
cell shows an mTOR dependent increase in p70S6K activity.  This increase in 
p70S6K activity provides the cell with a small level of resistance to amino acid 
depravation59.  In nutrient poor environments, the TSC1/TSC2 complex inhibits the 
phosphorylation of p70S6K.   
Recently studies have shown that the TSC1/TSC2 complex may also have a 
nutrient sensing path independent of the AKT pathway.  In cell lines where the 
TSC1/TSC2 was mutated out, the expected p70S6K dephosphorylation response to 
nutrient depravation is not seen.  This seems to suggest that the TSC1/TSC2 complex 
somehow signals nutrient levels to the cell, and that disturbing the TSC1/TSC2 
complex serves to destroy that sensing pathway10.   
 
Rheb 
Rheb is the last step in the PI3K pathway before mTOR.  Rheb is a small G-
protein activator of mTOR.  TSC2 is a GAP (GTPase-activating protein) for Rheb.  
Non phosphorlyated TSC2 acts as a Rheb inhibitor by converting the active GTP-
bound form of Rheb to the inactive GDP version.  However, when the TSC1/TSC2 
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complex is inactivated through AKT phosphorlyation, Rheb transforms into its active 
GTP-bound protein and upregulates mTOR60.   
Recently, Rheb has been shown to bind directly to the kinase domain on 
mTOR, in a GTP-dependant manner61.  Rheb’s high GTP levels allow it to bind 
mTORC1, causing a conformational change in mTORC162.  This conformational 
change leads to the activation and phosphorylation of the two best known 
downstream targets: 4E-BP1 and p70 S6K.  Gain of function Rheb mutants have been 
shown to be more active in promoting phosphorylation of 4E-BP1 and p70 S6K63.   
Most researchers would agree that Rheb binds mTOR but Rheb’s mechanism 
of interaction to activate mTOR remains unclear.  This is largely because it is difficult 
to detect direct interactions between Rheb and mTOR64.  It is also unclear what role 
GTP plays in the pathway.  Some labs have even suggested that Rheb and mTOR 
actually act in parallel pathways as opposed to the linear pathway presented here9.   
 
Phosphatidic Acid (PA) 
Phosphatidic acid (PA) is a lipid second messenger used in several 
intracellular pathways and regulates an ever expanding list of signaling proteins.  PA 
has been implicated as a mediator of mitogenic upregulation by hormones and growth 
factors65.  The precise mechanism by which PA acts on mTOR is yet unknown, but 
some labs have reported that PA is a requirement for mTOR to phosphorylate S6K65.  
After serum stimulation, a rapid rise in PA levels is observed, and correlates with 
activation of mTOR signaling in human embryonic kidney (HEK) cells.   
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PA is most commonly a product of the enzymatic activity of phospholipase D 
(PLD), addressed later in this discussion66.  PA is composed of a glycerol backbone 
with carbons 1 and 2 forming ester-links to fatty acids.  The terminal carbon group 
links to a phosphate group, forming the negatively charged polar head group.  There 
are at least three enzymes that are capable of PA generation: lysophosphatidic acid 
acyltransferase, and diacylglycerol kinase (DGK)67 and PLD.   
Diacylglycerol kinases (DGK) are a conserved family of lipid kinases that 
phosphorylate diacylglycerol (DAG) to produce PA.  DAG is a second messenger 
whose cellular levels have been shown to increase transiently with extracellular 
fluxuations of growth factors and hormones.  DAG is also activator of protein kinase 
C (PKC), and other GTPase-activating proteins including those in the Ras family of 
GTPases68.   
PA production by PLD can be suppressed by a reaction involving primary 
alcohols.  In the transphosphatidylation reaction, an inert phosphatidyl-alcohol is 
produced instead of PA when reacting PLD2 with primary, but not tertiary alcohols.  
In this reaction, the primary alcohol replaces the water molecule and acts as the 
nucleophillic acceptor.  The alcohol competes with the water to be the hydroxyl donor 
forming a phosphatidylalcohol.  This is a commonly used reaction as an in vitro PLD 
activity assay69.  The control experiment to rule out any effect of the alcohol not 
related to PLD is performed by using a tertiary alcohol instead of a primary alcohol 
that is not a substitute for PLD. 
Several labs have shown that PA production through PLD is an essential event 
for mitogenic activation of mTOR .  Cellular concentrations of PA are normally less 
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than 5% than that of phosphatidylcholine (PC), but during mitogenic activation the 
amount of PA within a cell increases, most likely due to PLD activation70.  Using 
0.3% 1-butanol, serum stimulated PA production can be effectively stopped65.  Using 
the same transphosphatidylation reaction, 1-butanol was able to almost completely 
block the serum stimulated phosphorylation of S6K1 and 4E-BP1.  The 
phosphorylation of serum stimulated activation of extracellular signal-regulated 
kinases (ERK1 and ERK2) was not affected by the presence of the 1-butanol.  This 
experiment established the specificity of 1-butanol on PA production and implicates 
the involvement of PA in the phosphorylation of S6K and 4E-BP171.  From these 
findings, it can be asserted that PLD production of PA plays an essential role in the 
mTOR signaling pathway.  The suppression of PA generated through PLD has been 
reported by a number of labs to inhibit the mTOR pathway in several cell phenotypes.   
The lab led by Dr. Jie Chen has also shown evidence that PA binds to mTOR 
at the FKBP12-rapamycin-binding (FRB) domain.  Small unilamellar vesicles 
(SUV’s) containing purified FRB fragment bound to PA in very low concentrations65.  
This binding was specific for PA as other phospholipids were unable bind the FRB 
with such specificity.  The FRB region is where the rapamycin-FKBP12 molecule 
binds mTOR as well.  It is hypothesized that the competition between the rapamycin-
FKBP12 complex and PA for the FRB site may be one of the regulating factors in 
mTOR activation71.  Researchers previously suggested that the rapamycin-FKBP12 
molecule induces a conformational change in the structure of mTOR72.  However new 
data suggests the effects of rapamycin are realized through the competitive interaction 
between mTOR’s FRB and PLD generated PA.  Yet a third hypothesis suggests that 
 17 
the pH locally around mTOR is reduced by PA generated PLD.  mTOR is then 
pronated in a way that promotes its kinase activity, or allows for interaction with yet 
unknown promoter substrates53.   
Attempts at corroborating mTOR phosphorylation studies using exogenously 
provided PA have been inconclusive.  Some labs have reported exogenously supplied 
PA was able to incorporate easily into cellular membranes and participate in cellular 
functions73.  Others however, reported that signaling was disrupted in siRNA PLD2 
knockdown cells, even with the presence of exogenously provided PA74.  Recently 
there have been some questions about the validity of studies involving exogenously 
provided PA.  It is difficult for PA to cross cellular membranes and reach appropriate 
sites to engage mTOR, and exogenously provided PA may activate mTOR as a result 
of another, yet unknown pathway53.   
 
The Role of mTOR in Hypoxia 
During low oxygen conditions, mammalian cells immediately down-regulate 
energy consuming processes75.  Translation is one of the first processes to be effected 
as the cell seeks to stave off the impending energy crisis.  Hypoxia also upregulates 
HIF-1, a transcription factor which activates genes required for the cell’s adaptation 
to the new environment13.  Because it is yet unknown what pathways regulate HIF-1 
in response to hypoxia, some have suggested mTOR as a potential mediator of the 
extracellular condtions76.  However, other studies have shown that mTOR and S6K1 
can respond to amino acid availability independently of the TSC1/2 pathway77.  
Hypoxia mimics rapamycin causing the dephosphorylation of mTOR and its 
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downstream effecter proteins, 4E-BP1 and S6-Kinase.  These effects have been 
observed independently of the growth factors previously discussed in this review.  
These findings suggest yet another unresolved pathway that mTOR may use to effect 
the cell78.   
 
Downstream Molecules of mTOR/Raptor (TORC1) 
Ribosomal S6 Kinase 
The best characterized function of mTOR is translation regulation72.  The S6K 
isoform, S6K-1 is a major ribosomal protein in mammalian cells, and responsible to 
phosphorylate the S6 ribosomal protein79.  The ribosomal S6 subunit of the 40S 
ribosome selectively increases translation of some of the mRNA’s containing the 5’-
Terminal Oligopyramidine Tract (5’-TOP)39.  mRNA’s with a 5’-TOP often serve to 
encode ribosomal proteins and other transcription regulation proteins thereby 
upregulating transcription80.  S6K is independent of mTOR81 however, even low 
concentrations of rapamycin are thought to inhibit the phosphorylation activity of 
S6K24.  While the actions of S6K are not well understood48, S6K1 likely plays an 
important role in the regulation of cell cycle progression, cell growth and cell 
proliferation82.   
Structurally, the S6K protein is divided into four regions: the acidic NH2 
terminus, the catalytic domain, a linker region and a basic COOH- terminus 
containing an autoinhibitory pseudosubstrate domain83.  Current data suggests that 
S6K remains in an inactive state with its acidic NH2-terminus interacting with the 
basic COOH region, stabilizing the protein.  This conformation allows the 
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pseudosubstrate region to autoinhibit the catalytic domain of S6K.  After 
phosphorylation of several C-terminal sites, the S6K undergoes a conformational 
change and releases the pseudosubstrate, allowing the phosphorylation of T389 in the 
catalytic domain82.   
The mTOR and PI3K pathways can phosphorylate at least eight sites on S6K.  
These phosphorylation events are known to require several mediator molecules 
including PDK1, AKT, PKC, and the small G proteins Cdc42 and Rac182.  It is likely 
that there are other yet unknown mediator molecules.  Only the phosphorylation of 
T229 on S6K’s activation loop of the kinase domain has been described84.  The 
remaining phosphorylation sites, while identified, remain less well understood.  Two 
phosphorylation sites serine 371 and threonine 389 are known to be required for S6K 
activity85.  Experiements show that mTOR can phosphorylate T389 directly in vitro 
while the kinase responsible for S371 is not yet known33.  However, incubation with 
rapamycin causes dephosphorylation of threonine 229 and serine 404 suggesting 
mTOR’s involvement with those residues as well.  
Additionally, evidence now shows that mTOR phosphorylation is mediated by 
p70 S6 Kinase52.  This feedback mechanism phosphorylates SER-2448 on mTOR, 
and does not appear to be controlled by the AKT pathway.  This may be a negative 
feedback mechanism86.   
It has been shown that inhibition of mTOR signaling by rapamycin treatment 
leads to a dramatic decrease in rRNA gene transcription and pre-rRNA processing87.  
This includes the dephosphorylation of T389, the principle rapamycin-sensitive site, 
leading to the kinase inactivation of S6K51.  This evidence suggests that mTOR 
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signaling is a vital link in sensing nutrient availability and regulating ribosome 
biogenesis on the basis of that information88.  Inhibition of mTOR signaling has been 
shown to inhibit translation as well, but in a less dramatic fashion than its inhibition 
of transcription89.  In mice, disruption of S6K1 leads to reduced animal size, 
suggesting a role for S6K1 in the control of cell size and growth.  Amino acid 
depletion also causes S6K dephosphorylation, through the mTOR pathway, in a 
manner which is reversible by the replenishing of the addition of amino acids.   
Ribosome synthesis is a hallmark indicator of cellular growth regulation.  As 
nutrients become more readily available, cells upregulate ribosome synthesis, 
allowing for a rapid size increases and proliferation.  As was previously discussed, 
this process is energy intensive and must be strictly regulated for survival purposes.  
HeLa cells, for example, produce about 7,500 ribosomes per minute, requiring the 
transcription of 150-200 rRNA genes and involving the synthesis of approximately 
300,000 ribosomal proteins47.  This tightly regulated process would be impossible 
except for the systematic interactions between nutrient sensing pathways and with 
coordinated support from assembly factors, ribonucleases, small nucleolar 
ribonucleoprotein particles and RNA helicases.  This has been previously explained 
by Fingar et al. in their article on mTOR.   
“If the rate of cell growth is unable to keep up with the rapid rate of 
cell division, then cell proliferation cannot be sustained, since cells 
would progressively loose mass and size with each division cycle, 
resulting in inevitable cell death.  Therefore, proliferating cells exhibit 
tight coordination between cell growth and cell cycle progression.  In 
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addition, such coordination ensures that individual cells, and indeed 
organs and whole organisms, maintain a characteristic size.” 83  
Recently a second S6 Kinase was discovered, S6K241.  S6K2 shows an 80% 
homology to S6K1 and is also phosphorylated in a rapamycin dependant manner.  
Unlike its cytosolic counterpart S6K1, however, S6K2 is nuclear, due to its C-
terminal nuclear localization signal (NLS)90.  Much less is known about S6K2 than 
S6K1, but current models suggest redundant functions.  S6K1 is thought to play a 
more crucial role in growth control than S6K250.   
The membrane-to-nucleus PI3K-mTOR pathway is beginning to reveal itself 
as more than just a linear pathway.  Mounting evidence points to the hypothesis that 
the PI3K pathway operates under the nutrient sensing influence of mTOR only to a 
certain degree.  Amino acid and energy sufficiency are mediated by mTOR primarily, 
while growth factors, hormones, and mitogens sufficiency are conveyed through the 
PI3K pathway and then to mTOR.   
 
4E-BP1 
Cells treated with mTOR inhibitor rapamcyin arrest at the G1/S boundary and 
mimic the physiological state of starved G0 cells25.  mTOR kinases, in the presence of 
adequate amino acids, upregulate the signaling pathways by activating eukaryotic 
translation initiation factor 4 E (eIF-4E) protein synthesis, effectively inducting G1 
progression91.  The 12 kDa polypeptide 4E-BP1 is a strong repressor or eIF-4E, 
important for translation.  By regulating energy use within the cell, mTOR serves as 
an effective gatekeeper.   
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In its inactive state when nutrients or growth factors are scarce, 4E-BP1 is 
hypophosphorylated and binds tightly to the 7-methylguanosine cap-binding protein 
eIF4E to inhibit eIF4E function91.  Upon the return of adequate nutrients and growth 
factors, 4E-BP1 is phosphorylated and dissociates from eIF4E.  eIF-4E is then able to 
specifically recognize and bind the 5’cap on a nuclear transcribed mRNA.  Almost all 
nuclear transcribed mRNA contain a 5’ cap structure; m7GpppN, (where ‘m’ stands 
for any methyl group and ‘N’ any nucleotide)92.  eIF-4E is also available to bind the 
scaffolding protein eIF4G and assemble the translation initiation complex.  While the 
translation initiation complex forms, eIF4G also interacts with eIF3, recruiting the 
40S subunit to the 5’ end of the mRNA93.  Because the binding sites for 4E-BP1 and 
eIF4G overlap on eIF4E, their binding is competitive and mutually exclusive, 
ensuring 4E-BP1’s ability to regulate eIF4E’s activity. 
Phosphorlyation and activation of 4E-BP1 is sensitive to mTOR inhibitors 
including rapamycin and other PI3K pathway inhibitors.  Studies in vitro show that 
immunoprecipitated mTOR phosphorlyates threonine 37 and threonine 46 on 4E-
BP1, suggesting mTOR as the active kinase in vivo33.  These two sites are considered 
priming sites, as phosphorylation of serine 65 and threonine 70 must follow for eIF-
4E to be released by 4E-BP1.  The kinase for the phosphorylation of these sites is yet 
unknown, but mTOR may also act as the kinase there.  In all, 4E-BP1 has seven 
known phosphorylation sites: Thr 37, Thr 46, Ser 65, Thr 70, Ser 83, Ser 101 and Ser 
11292.  As is expected then, inhibition of mTOR by rapamycin results in the 
hypophosphorylation of 4E-BP1.   
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TOR “Signaling Motif”  
Both S6-Kinase and 4E-BP1 contain a TOR Signaling (TOS) motif, which 
may be recognized by the Raptor-mTOR complex.  A functional TOS motif is 
required for mTOR to phosphorylate S6K1 and 4E-BP1 in vivo, as destroying this 
domain mimics rapamycin treatment of mTOR94.  Studies show that an inactive TOS 
motif on 4E-BP1 is unable to bind mTOR and results in abnormally small cell growth 
and small cell size95.  The mTOR/raptor/4E-BP1 complex will not properly form in 
the absence of a functional TOS motif.  These experiments lead to the hypothesis that 
raptor interacts with mTOR to form a substrate presentation scaffold, and without the 
properly functioning regions, is ineffective at phosphorlyating downstream 
substrates43.   
The homology demonstrated in the TOS regions of S6K and 4E-BP1 is not 
unique, however, and is demonstrated in many other proteins72.  This lack of 
specificitiy makes it difficult to identify sequences for which mTOR has a remarkable 
affinity.  Also, phosphorylation sites are not conserved between the two molecules.  
This has lead some to propose that mTOR associated proteins may actually determine 
the substrate preference, leaving mTOR’s kinase domain with no preference in 
substrate33.  It is difficult then to prove with any certainty that S6K and 4E-BP1 are 
direct substrates of the mTOR-raptor complex.   
Due to the nature of the many substrates that are apparently involved with the 
mTOR signaling path, there is mounting concern about the disruption of those 
proteins in vitro83.  Recent studies show that mTOR and it associated proteins are 
easily disrupted with nonionic detergents.  This may be one explanation for the 
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apparent disparity in kinase activity experiments and provide insight into why 
mTOR’s in vitro kinase activity correlates poorly with the activation and 
phosphorylation of expected downstream targets in vivo83. 
Evidence continues to mount pointing to a possibility that there are one or 
more intermediate kinases that regulate the downstream molecules of mTOR.  This 
kinase or may be regulated by or associate with mTOR in interactions that are yet 
unknown.  This possibility should continue to drive research forward to elucidate the 
precise mechanism by which mTOR is regulated.   
 
Clinical Applications 
As was previously discussed, mTOR and its pathways are commonly 
overexpressed or mutated in cancer.  Clinical studies on several prototype mTOR 
inhibitors, all rapamycin analogs, (CCI-779 [Wyeth], RAD001 [Novartis] and 
AP23573 [Ariad Pharmaceuticals] are currently taking place16.  However, these drugs 
have only shown promise is a few cancers.  The overall response to rapamycin 
treatments has been variable, with success often linked to certain cell types.   
Several unexpected results of rapamycin-analog treatments have presented 
themselves.  The first is the existence of a strong negative feedback loop from S6K to 
AKT49.  This loop inhibits AKT when mTOR is activated which can promote cell 
survival and chemoresistance48.  The very cancerous cells which the drug is 
attempting to eradicate may, in fact enter a survival mode, allowing them to survive 
and proliferate under stressful conditions such as nutrient or space deprivation.  The 
second unexpected result of treatment is that prolonged rapamycin treatment has been 
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shown to lead to the inhibition of the mTORC2-RICTOR complex.  This complex 
was previously thought to be insensitive to rapamycin.  The cause for this finding is 
yet unknown, but it is speculated to be mediated through the AKT pathway.  
The development of safe, effective pharmaceutical agents to counteract the 
dysregulation of the AKT/mTOR pathway in cancer should be a key focus of mTOR 
research right now.  However, this goal will not be able to be reached until the 
complexity of the mTOR protein complex and the crosstalk between other signaling 
molecules are more fully realized.  Defining the connection between the mTOR 
associated proteins and its kinase activity is an important challenge for the future.   
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II.  HYPOTHESIS AND SPECIFIC AIMS 
 
We hypothesize that mTOR can be overexpressed in a mammalian 
system and a complete study of this expression (protein activity and 
subcellular localization) can be pursued, taking advantage of an HA tag.   
 
AIM 1:   
Prepare an HA-tagged mTOR expression plasmid.   
 
AIM 2:  
Generate three HA-tagged mTOR mutated plasmids by site directed mutagenesis.  
Including:  
PA binding deficient R2109A 
Kinase Dead D2357E 
Rapamycin Resistant S2035T 
 
AIM 3: 
Detect protein expression of plasmids by Western blotting; probe with anti-HA and 
anti-mTOR. 
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AIM 4:  
Determine enzyme activity of overexpression plasmids (mock, HA-mTOR, Kinase 
Dead) using KLISA, Mass Spectrometry, or gamma ATP to detect phosphorylation of 
mTOR substrates.   
Substrates 4E-BP1, S6K 
Use Rapamycin, a known mTOR inhibitor as a negative control.   
 
AIM 5:   
Investigate the effects of mTOR transfection on gene expression and subcellular 
localization.  
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COS-7 cells were purchased from American Type Culture Collection (ATCC) 
(Rockville, MD).  mTOR, PLD1, PLD2 and, S6K Taqman gene expression assays 
purchased from Applied Biosystems (Foster City, CA).  Protease Inhibitor cocktail 
set III, microcystin-LR and, K-LISA mTOR activity kit purchased from Calbiochem ( 
San Diego, CA).  Dulbecco’s Modification of Eagle’s Medium (DMEM) purchased 
from Cellgro (Herndon, VA).  HA-Tag (6E2) Mouse mAb purchased from Cell 
Signaling Technology (Danvers, MA).  TrichromRanger prestained molecular weight 
marker mix, 4-20% Precise Protein gels and, Scintiverse II scintillation cocktail 
obtained from Fischer Scientific (Chicago, IL).  Enhanced chemiluminescence (ECL) 
Western blotting detection reagents purchased from GE Healthcare (Piscataway, NJ).  
phCMV2-HA vector (4.26 kb) purchased from Gene Therapy Systems (San Diego, 
CA).  Various primers purchased from Integrated DNA Technologies Inc. (Coralville, 
IA).  Lipofectamine, plus reagent, Opti-MEM reduced serum medium, Quant-iT 
Ribogreen RNA assay kit, dNTP’s, SuperScriptII reverse transcriptase, random 
primers, single strand reverse transcriptase buffer, RNase out, Deoxyribonuclease I 
and, DTT purchased from Invitrogen (Carlsbad, CA).  UltraClean Plasmid Prep Kit 
purchased from MOBIO Laboratories, Inc. (Carlsbad, CA).  Quick Ligation Kit, Taq 
DNA Polymerase and ThermoPol Buffer, Restriction Enzymes and their buffers, 
Lambda DNA-HindIII Digest and, Antarctic Phosphatase, purchased from New 
England BioLabs Inc. (Ipswich, MA).  Homo sapiens FK506 binding protein 12-
rapamycin associated protein 1 (FRAP1) Human cDNA clone (also known as mTOR) 
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purchased from OriGene Technologies, Inc.  (Rockville, MD).  [32P] γ−ATP (500 µci) 
purchased from Perkin Elmer (Waltham, MA).  RNeasy minikit, Quiaquick gel 
purification kit and, QIAprep Spin Miniprep kit were  purchased from Qiagen Inc. 
(Valencia, CA).  4E-BP1 (FL), HA-probe (Y11), α-myc-TRITC IgG antibody and, a-
HA-FITC IgG antibody purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA).  Monoclonal Anti-HA, Influenza Hemagglutinin Protein (HA-Tag) and, 
Influenza Hemagglutinin (HA) Peptide purchased from Sigma (St. Louis, MO).  
QuikChange XL Site-Directed Mutagenesis Kit, 96 well PCR plates, DH5α gold 
cells, and Brilliant II QPCR master mix purchased from Strategene (La Jolla, CA.).  
P70 S6 Kinase (T412E), active purchased from Upstate Biotechnology (Lake Placid, 
NY).  ExoSAP-IT, DNA Ladder (1 KB), Agarose, molecular biology grade ultra pure 
water and, 10X TAE buffer purchased from USB Corporation (Cleveland, OH).  
Vectashield mounting media purchased from Vector Labs (Burlingame, CA).  Ion 
exchange chromatography cellulose phosphate paper purchased from Whatman 




DH5α Transformation  
 
This experiment was begun with a Homo sapiens FK506 binding protein 12-
rapamycin associated protein 1 (FRAP1) Human cDNA clone (known for the 
purposes of this thesis as mTOR) purchased from OriGene Technologies, Inc.  This 
DNA clone was the starting point of the thesis and the building block from which the 
four other plasmid constructs would come.   
The filter containing the purchased, dried DNA clone was placed in a sterile 
eppendorf with 10 µl ultrapure water to achieve a final concentration of 100 ng/µl.  
DH5α cells (100 µl) were thawed on ice to which 50 ng of eluted plasmid was added.  
The cell-plasmid mixture was occasionally swirled and incubated on ice for 30 
minutes.  The mixture was then heat shocked for 45 seconds at 42° C, and chilled on 
ice for 2 minutes.  Room temperature SOC media (900 ml) was added and the cells 
incubated at 37°C for 1 hour in a shaker at 230 RPM.  After 1 hour 150 µl of the 
SOC-cell mixture was spread onto LB/Agar/Ampicillin solid media plates.   
Individual colonies of the DH5α transformed with pCMV6-XL4-mTOR were 
selected and inoculated in 5 ml LB/Ampicillin.  These were incubated at 37°C for 8 
hours before mixing 850 µl of the bacterial culture and 150 µl glycerol to make 
glycerol stocks.  Glycerol stocks were stored at -70°C.   
 
DNA Preparation – Maxiprep  
For maxiprep DNA preparation we used the UltraClean Plasmid Prep Kit 
purchased from MOBIO Laboratories, Inc.  The manufacturer’s instructions were 
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followed to obtain large quantities of DNA from cell cultures.  One ml bacterial 
culture was added to 400 ml LB/Ampicillin and incubated in the shaker, overnight at 
37°C.  The next day the culture was prepared per the protocol provided with 
MOBIO’s Plasmid Prep Kit.  The cells were pelleted at 4500xg and resuspended in 5 
ml Solution 1.  The pellet was lysed by alkaline treatment by adding 10 ml Solution 2, 
and inverting 5 times.  Thirty ml Solution 3 neutralized the mixture, after which it 
was inverted again 5 times.  The cell mixture was centrifuged for 20 minutes at 
4500xg, which allows for the separation of the DNA from the proteins.  The pellet 
and floating protein and lipid mixture at top of the liquid were discarded.  The filter 
column was centrifuged dry at 3600xg for 5 minutes.  Then 2 ml of 65C ultrapure 
water was added to the column and centrifuged into a clean centrifuge column.   
 
Restriction Enzyme Digestion 
Five hundred ng of plasmid was incubated with 1 µl of the appropriate buffer, 
a minimum of 20 units of enzyme as required, and 1 µl of BSA as required.  All 
restriction enzymes were obtained from New England BioLabs, and the 
manufacturer’s instructions for digestion reactions were followed.  One unit of 
enzyme is defined as the amount of enzyme required to digest 1 µg of λ DNA in 1 
hour at 37°C in a total reaction volume of 50 µl.  The total volume of the reaction was 
then taken to 10 µl and incubated at 37°C for a minimum of 2 hours.  After 
incubation, 2 ml gel loading buffer was added to each digestion and the mixture was 
loaded into a 1% agarose gel.  The gel was run at 100V for approximately 40 minutes, 
until the marker bands were clearly separated.  Images of the gels were captured 
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under ultraviolet light with Kodak’s Gel Logic 200 image system using Capture GL 
Molecular Imaging Software version 4.0.1.   
 
Mutagenesis 
Mutagenesis was performed as outlined in Stragagene’s QuikChange XL Site-
Directed Mutagenesis Kit.  Fifty ng of purified plasmid was added to 5 µl 10X 
mutagenic buffer.  Sense and antisense mutagenic primers (0.65 µl) were then added.  
Primers were designed at www.idtdna.com and purchased from that same company 
(Tables 1, 2).  The primers were stored at a stock concentration of 200 ng/µl in TE, 
pH 7.5.  One µl dNTP’s, three µl QuikSolution, and ultrapure water to 49 µl were 
added.  Next 1 µl Pfu Turbo polymerase was added, the mixture mixed and 
centrifuged.  The mutagenesis reaction was placed in the PCR machine and cycled.  
After the PCR reaction was complete, 1 µl Dpn I was added and allowed to react for 
1 hour at 37°C.  This mutagenic, Dpn I-treated PCR reaction was then used to 
transform XL10 cells. 
 
XL-10 Cell Transformation 
To transform the mutagenesis reaction, 45 ul XL10 competent cells were 
added to 2 µl β-Mercaptoethanol and incubated on ice for 10 minutes.  Next, 2 µl of 
the Dpn I-treated mutagenesis reaction was added, and incubated for 30 minutes on 
ice.  The mixture was then heat shocked at 42°C for 30 seconds after which it was 
placed on ice for 2 minutes.  NZY+ media (450 µl) was preheated to 43°C and added 














Mutagenic primers were designed to introduce two point mutations into 
pCMV6-XL4-mTOR to introduce two new restriction sites, HindIII and MfeI to 
the plasmid.  These sites allowed for removal of the mTOR insert and ligation 
into the phCMV2-HA vector.  The sequence underlined and in red above is 
the HindIII point mutation.   The sequence underlined and in blue represents 
the MfeI mutation.  After mutation, digestion with HindIII and the NotI, a site 
which was already present in the mTOR sequence, released the mTOR insert 
from the pCMV6 backbone and allowed for purification of the sequence.  The 
sticky ends created by digestion with HindIII and NotI of mTOR correspond to 
the same sticky ends created in the phCMV2-HA plasmid with the same 
digestion.  These complementary sticky ends provided ideal ligation 
conditions.   
 





















Mutagenic primers were designed to introduce two point mutations into 
phCMV2-HAmTOR-WT to introduce new restriction sites to the plasmid.  
These sites allowed for the detection of the mutation by restriction enzyme 
digestion after cells are transformed.  The sequences underlined and in red 
represent the mutation sites.  The D2357E plasmid contains an EcoRI 
mutation, the R2109A plasmid contains an NruI mutation and the S2035T 
contains an AflIII mutation.   
Primer Mutagenic Primer Sequence 
mTOR D2357E 
Sense 
5’ - GATCCTGCACATTGAATTCGGGGACTGCTTTG - 3’ 
mTOR D2357E 
Anti-sense 
5’ – CAAAGCAGTCCCCGAATTCAATGTGCAGGATC – 3’ 
mTOR R2109A 
Sense 
5’ – CTCTATTATCATGTGGTCGCGAGAATCTCAAAGCAGC – 3’ 
mTOR R2109A 
Anti-sense 
5’ – GCTGCTTTGAGATTCTCGCGAACACATGATAATAGAG – 3’ 
mTOR S2035T 
Sense 
5’ – GCCTGGAAGAGGCAACACGTTTGTACTTTG– 3’ 
mTOR S2035T 
Anti-sense 
5’ – CAAAGTACAAACGTGTTGCCTCTTCCAGGC– 3’ 
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230 RPM.  After incubation, 200 µl of the transformation reaction was plated on 
LB/Agar/Ampicillin solid media plates and incubated overnight at 37°C.   
 
DNA Preperation - Miniprep  
For DNA miniprep we used Qiagen’s QIAprep Spin Miniprep Kit and 
followed the manufacturer’s detailed instructions.  Briefly, the 3 ml cultures of 
transformed XL-10 or DH5α cells were pelleted at 4000x g for 10 minutes and the 
supernatant removed.  The pellet was resuspended in 250 µl buffer P1 and transferred 
to labeled 1.5 ml eppendorf tubes per the instructions provided in Qiagen’s Plasmid 
miniprep kit.  Buffer P2 (250 µl) was added, and the tube inverted 6 times.  Buffer N 
(350 µl) was added, and the contents of the tube centrifuged at 18,000x g for 10 
minutes.  The supernatant was passed through the Miniprep columns by centerfuging 
at 18,000x g for 2 minutes, flow through being discarded.  Column filters were 
washed with 750 µl buffer PE and centrifuged to dry.  Filters were eluted with 50 µl 
buffer EB into clean eppendorf tubes.   
 
DH5α Transformation with pCMV6-mTOR 
DH5α cells were transformed with pCMV6-mTOR plasmid.  The procedure 
follows a similar protocol to the one described for the transformation of pCMV6-
XL4-mTOR plasmid.  Fifty ng of plasmid was used to transform 100 µl competent 
DH5α cells.  Individual colonies were selected from the solid agar/ampicillin plates 
and 5 ml cultures of LB/ampicillin were inoculated and grown for 5 hours at 37°C.  
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The two most confluent cultures after 5 hours were used to prepare the 200 ml 
LB/ampicillin broth for maxiprep.   
 
Purification of mTOR Insert 
Five µg of pCMV6-mTOR and 50 Units of HindIII were combined with the 
appropriate buffers and incubated at 37°C for 6 hours.  After inactivation of HindIII 
for 20 minutes at 65°C, 50 Units of NotI was added with the appropriate buffer.  This 
mixture was incubated overnight at 37°C.  Gel purification of the mTOR insert 
proceeded per Qiagen’s QIAquick Gel Extraction protocol.   
 
Digestion and Dephosphorylation of phCMV2-HA 
Five µg of the phCMV2-HA vector was combined with 50 Units of HindIII 
and the appropriate buffers.  This mixture was incubated for 6 hours at 37°C.  After 
heat inactivation of HindIII for 20 minutes at 65°C, 50 Units of NotI were added with 
appropriate buffers and the mixture was incubated overnight at 37°C.  The phCMV2-
HA vector, with HindIII and NotI sticky ends was dephosphorylated with Antarctic 
Phosphatase.   
 
Ligation of Hind IIIphCMV2-HANot I and Hind IIImTORNot I 
Fifty ng of dephosphorylated Hind IIIphCMV2-HANot I vector was combined 
with a 3-fold molar excess of purified Hind IIImTORNot I insert.  Ten µl of 2X ligation 
buffer was added, followed by 1 µl of T4 DNA Ligase.  The mixture was centrifuged 
and incubated at room temperature for 5 minutes.  The ligation reaction was chilled 
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on ice and then used to transform DH5α cells.  Transformation of DH5α cells with 
the phCMV2-HAmTOR-WT plasmid proceeded as outlined previously with 
adjustments made for the ligation mixture.  Five µl ligation mixture was added to 100 
µl XL-10 cells and mixed by gently pipetting up and down.  The transformation 
reactions were plated on LB/agar/Kanamycin solid media plates.  These plates were 
incubated overnight at 37°C.   
 
Generation of the phCMV2-HAmTOR-WT Plasmid 
Primers were ordered from www.IDTDNA.com to allow sequencing around 
the ligation site of the phCMV2-HAmTOR-WT plasmid (Table 3).  PCR primers 
were stored in stock concentrations of 100 pmol/µl.  Each PCR reaction contained 15 
µl PCR buffer, 1 µl dNTP’s, 1 µl MgSO4, 1 µl primer set, 42 µl water, 0.25 µl Taq 
Polymerase DNA and, approximately 10 pg plasmid.  The sense/antisense “535 
primer set” were used in one reaction and a second reaction contained the 
sense/antisense “716 primer set.”  Ten µl of PCR sample was added to 4 µl of 
ExoSAPit and mixed.  The reaction was incubated at 37°C for 15 minutes followed 
by 80°C for 15 minutes.   
 
Cell Transfection and Lysate Preparation 
Plasmid transfection to mammalian COS-7 cells was carried out under 
standard transfection conditions, using Invitrogen’s Lipofectamine and Plus reagents 
as vehicles for the plasmids to enter the COS-7 cells.  Six well plates were used, wells 





















PCR Primers were designed against phCMV2-HAmTOR-WT to enable 
sequencing of the ligation site near the HA tag.  The 535 primer set gave 
fragment 535 bp in length, and the 716 primer set gave a 716 bp fragment 
when run on a 2% agarose gel.   
 
Primer Primer Sequence 
HAmTOR-535 
sense 
5’ – AATGGGCGTGGATAGCGGTTTGAC-3’ 
HAmTOR-535 
antisense 
5’ – CTAGATGTGGTGGCAGCGGTGGTG – 3’ 
HAmTOR-716 
sense 
5’ – GCAAATGGGCGGTAGGCGTGTA – 3’ 
HAmTOR-716 
antisense 
5’ – ACTGGGTCATTGGAGGGGAGGAGGTTC – 3’ 
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5 µl of Lipofectamine and 5 µl of Plus reagent along with the proper amount of 
plasmid.  After a 48 hour incubation at 37°C, with controlled humidity and 5% CO2, 
the cells were harvested.  Cell lysates were taken from COS-7 cells transfected with 
each of the 4 plasmids.   
Lysates were obtained using a lysis buffer modified from Kim et al.10; 50 mM 
Tris HCL, 100 mM NaCl, 10% Glycerol, 1% Tween 20, 1 mM EDTA, 25 mM NaF, 
50 mM B-Glycerolphosphate, 1:200 Sigma Phosphatase Inhibitor Cocktail I, 1:200 
Calbiochem Protease Inhibitor Cocktail Set III.  This buffer was named KLISA Lysis 
Buffer (KLB).  Cells were scraped from their wells, and rinsed with lysis buffer 
before being sonicated for 10 seconds.  After sonication, the fragments were pelleted 
via centrifugation for 2 minutes at 14,000 RPM.  Protein concentration was 
determined using the BioRad Protein Assay Kit, with the plates read by an Amersham 
BioTrack II plate reader.   
 
Western Blotting 
SDS-PAGE gels were run using Pierce 4-20% Precise Protein gels and 
TrichromeRanger Prestained Molecular Marker.  Gels were run at 70 Volts for 
approximately 90 minutes.  The proteins embedded in the SDS-PAGE gels were 
transferred to PVDF membranes during a 70 mA, 1.5 hour transfer.  The PVDF 
containing the proteins were dried overnight and Western Blotting was performed the 
next day.  Western Blotting was performed with 1:750 anti-mTOR and 1:5000 anti-
rabbit IgG and Horseradish Peroxdase.  Additional experiments used 1:1000 anti-HA 
Primary antibody and 1:5000 anti-mouse IgG.  Amersham’s ECL Reagents were used 
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to wash the PVDF’s and then in a dark room, mounted to X-Ray film in a cassette.  
Film was developed 24 to 48 hours later.   
 
Kinase Assay  
A recipe for a 2X mTOR Kinase Assay buffer was found published by Kim et. 
al. 39.  Kim’s Kinase Buffer is composed of; 50 mM Hepes-KOH (pH 7.4), 100 mM 
KCL, 40% glycerol, 20 mM MgCl2, 8 mM MnCl2, 2 mM DTT, 100 µm ATP.   
Using 19 µl of 2X Kim Kinase Assay Buffer, 20 µl COS-7 cell lysate and 1 µl 
of either p70 S6 Kinase (T412E), or 4E-BP1, the cell lysates were tested for kinase 
activity.  The mass spectrometer used SAX2 Protein Chips by Ciphergen.  1 µl SPA 
supernatanent was loaded on top of each of the samples and allowed to dry.  The 
chips were then run in the mass spectrometer and the data analyzed for peaks 
indicating phosphorylated proteins.   
A second, different, kinase assay used COS-7 cell lysates that were 
immunoprecipitated with anti-mTOR antibodies to concentrate the mTOR.  This 
assay consisted of 140 µl cell lysate, 100 µl LB2, 8 µl HA-agarose beads were 
combined and incubated at 4°C in a rotator for 2 hours.  After 2 hours the beads were 
washed with cold LiCL and NaCl and resuspended in Lysis Buffer.  Kim’s 2X Kinase 
buffer was modified to create a 4X buffer, while the glycerol concentration was 
reduced to 20%.   
For the [32P] γ−ATP kinase assay, 12.5 ml Kim’s 4X buffer, 1 µci 
[32P] γ−ATP, 23.8 µl H20, 12.5 µl immunoprecipitated HA-agarose bead suspension, 
and either 1 µl S6K or 1 µl 4E-BP1 were incubated for 25 minutes at 37°C.  After 
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incubation, the reactions were boiled for 7 minutes, with strong vortexing every 2 
minutes.  Fifty µl of the supernatant was loaded into the Pierce 4-20% Precise Protein 
gel.  Gel was run at 70 V for approximately 100 minutes, or until the wavefront was 
run off the gel.  After the proteins were transferred to a PVDF membrane, the PVDF 
was loaded into a film cassette with X-ray film and stored overnight at -70°C.  X-Ray 
films were exposed for a period of 24 hours up to two weeks.   
 
Real Time PCR 
COS-7 cells were transfected with pc-DNA-myc-PLD2, and phCMV2-
HAmTOR-WT plasmids under conditions described previously.  Cell lysate was 
obtained by scraping the wells and rinsing the lysate with TBS.  Using the Qiagen 
RNeasy Minikit, RNA was extracted from the cell lysate.  The obtained RNA was 
subject to DNase treatment, following the protocol provided with Invitrogen’s 
DNAase I kit.  Next, an aliquot of the RNA was removed for quantification purposes.  
A 6.3 µl aliquot of RNA was quantified against an RNA standard using Molecular 
Probes Ribogreen RNA Quantitation Kit.  Then an equal quantity of RNA from each 
sample of DNA treated RNA was then reverse transcribed to cDNA.  The cDNA was 
then stored at -70°C.   
The RT-PCR is set up such that each transfection condition is probed with 
each of the probes designed against mTOR, S6K, PLD1 and PLD2.  A Master Mix of 
25 µl Stratagene Brilliant III Supermix, 1 µl of the respective probe/primer set, 3 µl 
Glucuronidase housekeeping gene probe/primer set, and 16 µl H20 was prepared for 
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the RT-PCR reaction.  The cDNA from each condition was added and the RT-PCR 
reaction run per the protocol provided with the supermix.   
 
Immunoflourescence Microscopy 
COS-7 transfected cells were fixed on glass coverslips by adding 1 ml 4% 
paraformaldehyde to each cover slip.  After a 10 minute incubation period at room 
temperature the paraformaldehyde was aspirated and cells permeabilized with 1 ml 
0.5% Triton X-100 in PBS.  Permeabilized cells were incubated on at room 
temperature for another 10 minutes.  Cells were then blocked with 1 ml 10% fetal 
bovine serum in 0.1% Triton X-100 in PBS.  Cells were incubated at room 
temperature for 4 hours.  Cells were probed by adding 1 ml of 1:1000 anti-HA FITC 
antibody conjugate in blocking buffer solution.  The 6-well plate was then covered 
and stored in the dark at 4°C overnight.  Any excess antibody was aspirated from the 
coverslips, and then the coverslips were washed with 1 ml PBS.  Probing with 1:1000 
TRITC Phalloidin dye followed.  After aspiration of anti-TRITC, 1 ml 1:2000 DAPI 
dye in PBS was used to stain nuclei.  Coverslips were incubated at room temperature 
for 5 minutes in the dark.  DAPI was aspirated and coverslips washed 3X with PBS.  
Coverslips were rinsed with ddH20 and allowed to air dry.  Coverslips were mounted, 
cell side down onto a glass microscope slide with a drop of Vectashield mounting 
media between the coverslip and slide.   
An Olympus Fluoview Laser scanning confocal microscope with a 60X 
objective was used to view the slides.  Images were captured and analyzed using 
MetaView v.6.0 software from Universal Imaging Co. 
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IV.  RESULTS 
 
Aim 1:  Prepare an mTOR Expression Plasmid. 
This lab has previously carried out studies using siRNA’s and Real Time 
PCR.  In her thesis, Farnaz Tabatabaian, M.S., developed a cell model of 
differentiated HL-60 cells and transfected them with siRNA’s using an Amaxa 
electroporator 96.  She was able to quantitate gene expression levels of PLD1, PLD2, 
mTOR and S6K.  Using siRNA technology, Tabatabaian sought to determine the 
impact of PLD gene silencing and its impact on mTOR and S6K levels.  These 
studies provided insight into protein expression and gene regulation within several 
different cell lines however, they lacked investigation into mTOR and its effect on 
cell lines.  This was largely because the lab had no way to over-express the mTOR 
protein kinase.  The development of such a molecular tool was one of the aims of the 
present thesis and provides a method to specifically investigate the role mTOR plays 
in the cell (Figure 4).   
 
pCMV6-XL4-mTOR 
An mTOR expression plasmid construct was readily obtainable from 
commercial sources.  For this thesis we purchased a Homo sapiens FK506 binding 
protein 12-rapamycin associated protein 1 (FRAP1) Human cDNA clone (also known 
as mTOR) from OriGene Technologies, Inc. (Rockville, MD).  This plasmid was 13, 
394 base pairs and contained an mTOR open reading frame of 8.7 kilobases linked to 
a 4.7 kilobase pCMV6-XL4 backbone (Figure 5).  This plasmid was named pCMV6-
XL4-mTOR.  However, the backbone of the plasmid did not contain any sequences  
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FIGURE 4:
Scheme outlining steps taken to develop an HA-tagged mTOR construct for
 this thesis.
44











M13 (-20) Forward primer
CMV primer







































for a tag.  A tagged protein as a result of overexpression of the plasmid in mammalian 
cells is needed for protein detection and kinase activity studies.  Thus, it was first 
necessary to subclone the mTOR open reading frame into a plasmid that would 
enable detection of the mTOR tagged protein.  For this purpose, we chose the 
phCMV2-HA vector that bears the Hemaglutinin epitope tag or “HA tag”.  The 
mTOR insert was removed, mutated and spliced into a phCMV2-HA vector.  The 
new vector, with the HA tag allowed for easier identification of the transfected 
mTOR.   
To establish a baseline purity and concentration the pCMV6-XL4-mTOR was 
transformed into DH5α cells.  The DH5α cell line is known for its high rate of 
transfection efficiency and high plasmid yield and therefore served as a suitable 
agent.  Using colonies obtained from the pCMV6-XL4-mTOR transfection, cultures 
were inoculated for miniprep.  Miniprep colonies were screened by restriction 
enzyme digestion for the presence of an insert of the correct length and proper 
restriction sites.  One colony which had the indications of the proper plasmid insert 
was used to inoculate a culture for maxiprep.  Using a plasmid prep kit, purified DNA 
was extracted from the cell culture.  The plasmid obtained from maxiprep was 
quantified and qualified by a 1% agarose gel and spectrophotometry.   
Restriction enzyme digestions were performed on the pCMV6-XL4-mTOR 
plasmid obtained from the maxiprep.  Using the supplied vector map, enzymes were 
chosen which would cut the plasmid in pieces large enough to discern if there were 
any irregularities between the plasmid which was ordered and that which was 
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received.  All gel bands that were predicted by the vector map were seen on the 1% 
agarose gel (Figure 6).   
 
Mutagenesis 
Mutagenic primers were designed to introduce new restriction sites into the 
phCMV6-XL4-mTOR plasmid (Table 1).  These mutations allowed the restriction 
enzyme removal of the mTOR insert from this plasmid and placement into the 
pCMV6 plasmid containing the HA tag.  Through mutation, the PCR primers added 
an additional MfeI site and an additional HindIII site near the promoter region of 
mTOR (Figure 7).  These additional sites were used to identify the mutated plasmid 
during restriction enzyme digestions as well as allow for ligation into the new vector 
(Figure 8).  The newly mutated plasmid was named pCMV6-mTOR.   
 
pCMV6-mTOR 
XL-10 cells from Stratagene were used when transforming the mutagenic 
plasmid due to their efficiency in transforming unmethylated plasmids.  Next, 26 
individual colonies of XL-10 cells transformed with pCMV6-mTOR were selected 
from the plates grown overnight (Figure 9).  Colonies that showed adequate growth in 
liquid broth overnight were selected for miniprep.  Restriction enzyme digestion 
performed on each of the 26 cultures to verify the MfeI and HindIII sites, indicating 
the presence of the mutated plasmid.  Additional restriction enzyme digestions were 



































Restriction Enzyme Digestion of pCMV6-Xl4-mTOR
FIGURE 6:
Restriction enzyme digestion of pCMV6-XL4-mTOR plasmid purified by 
maxiprep from DH5a cells.  Lane 1 shows expected banding at 5.2 (two 
bands), and 3.0 kb with XhoI digestion.  Lane 2 is a BamHI digestion with 
bands at 1.0, 1.9, 4.4, and 6.1 kb.  Lane 3 digestion shows expected 
banding at 9.2, 3.2, and 0.9 kb with EcoRI.  Lane 4 is a KpnI digestion 
showing the expected banding at 5.9 and 7.4 kb.  Lane 5 is 1 Kb DNA 
Ladder for reference.  Each digestion revealed the expected banding 
indicating the DH5a cells were able to be transformed and could produce 
an intact, pCMV6-XL4-mTOR plasmid.  The sum of the fragment lengths 
in each column equal the total length of the 13.3 kb pCMV6-XL4-mTOR 
plasmid. Digestion results were predicted using NEBcutter V2.0 software 
avaliable at www.neb.com, and the vector map provided by the 
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A.  Scheme outlining 1-Day Mutagenesis method used to mutaganize 
pCMV6-XL4-mTOR to pCMV6-mTOR.  
B.  PCR map outlining Mutagenic PCR reaction used in mutagenesis of 
pCMV6-XL4-mTOR to pCMV6-mTOR.  
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FIGURE 8:
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FIGURE 9:
Twenty six colonies of pCMV6-mTOR transformed XL-10 cells were 
selected for miniprep.  Purified DNA was run on a 1% agarose gel to 
screen for colonies containing a 13.4 kb plasmid.  These colonies will be 
subject to a restriction digest to screen for the proper HindIII mutation.  
Colonies 9, 16, 24, 25 and, 26 had no plasmid DNA and were excluded 
from the restriction enzyme digestion.  Colonies 5, 20, 21, 22 and 23 were 
suspected to contain a pCMV6-mTOR fragment but would be included in 





three to verify sequences of proper length (Figure 10).  This step will prevent using a 
plasmid that has an unsuspected deletion.   
Using the pCMV6-mTOR plasmid from the miniprep of clone number 3, 
DH5α cells were transformed.  A robust colony of DH5α cells was again selected 
and a maxiprep was performed to obtain a large quantity of pure pCMV6-mTOR.  
After maxiprep, the plasmid concentration and integrity of the pCMV6-mTOR 
plasmid were verified.  A 1% agarose gel revealed a distinct band at approximately 
13 kb indicating the presence of proper length DNA (Figure 11).  The 
spectrophotometer confirmed the DNA concentration estimate made from the gel, of 
300 ng/µl and a DNA purity of 1.994 (A260/280).   
The mTOR insert was next removed from pCMV6-mTOR and purified to be 
used in ligation.  This was accomplished through a HindIII/NotI double enzyme 
digestion of pCMV6-mTOR.  The addition of the Hind III site in the promoter region 
of the mTOR insert and the presence of a NotI site allowed removal of the mTOR 
insert from the pCMV6 backbone with a simple double digestion.  All restriction sites 
were mapped using Invitrogen’s Vector NTI software.  The resulting 8633 bp 
HindIIImTORNotI  fragment was visualized on a 1% agarose gel (Figure 12).  
 
Ligation of Hind IIIphCMV2-HANot I and Hind IIImTORNot I 
The phCMV2-HA vector with mTOR ligated into allowed for easier tracking 
of transfected mTOR for both immunoprecipitation and western blotting because of 
the HA tag present in the vector.  This lab has used the phCMV2-HA vector 










        XhoI / HindIII             PspOMI / HindIII         1 Kb             XbaI / HindIII  
      WT          Mutant           WT          Mutant                             WT        Mutant  
Digestion: 
Plasmid:
Restriction Enzyme Digestion 
FIGURE 10:
Restriction enzyme digestion of pCMV6-XL4-mTOR and pCMV6-mTOR.  
The pCMV6-XL4-mTOR was mutated by the addition of a HindIII 
restriction site to give the pCMV6-mTOR plasmid.  Each pCMV6-XL4-
mTOR plasmid is digested with the noted enzymes and run next to the 
mutated pCMV6-mTOR plasmid digested with the same enzymes.  
XhoI/HindIII double digestion of pCMV6-XL4-mTOR gives the expected 
bands at 5.2, 5.2 and 3.0 kb while digestion with the mutant pCMV6-
mTOR gives 5.2, 3.7, 3.0 and 1.5 kb bands.  The PspOMI/HindIII 
digestion of the pCMV6-XL4-mTOR plasmid gives the expected bands at 
11.1, 2.0, and 0.2 kb.  With the addition of the HindIII site in the mutant 
plasmid, the bands as expected are 7.2, 3.9, 2.1, and 0.2 kb.  XbaI/HindIII 
double digestion also reveals the presence of the additional HindIII site in 
the mutant as the W.T. bands are 9.0, 4.3, and 0.1 kb while the mutant 
has bands at 4.7, 4.3, 4.3, 0.1 kb.  
53
9416 bp (150 ng)
23130 bp (300 ng)








Verification of pCMV6-mTOR plasmid maxiprep integrity.  DH5α cells were 
transformed with pCMV6-mTOR and a maxiprep was performed.  
Concentration of pCMV6-mTOR purified plasmid was estimated at 300 ng/µl 
using λ DNA as a reference.  Each lane contains the indicated amount of 
purified plasmid.  For confirmation the plasmid prep (1:10 dillution) was also 
quantitated by spectrophotometry at O.D. 260/280: 
Concentration = 323 ng/µl
DNA Purity (A260/280) = 1.994

























































A.  Restriction enzyme digestion of mutated plasmid, pCMV6-mTOR and HA-
tagged vector.  phCMV2-HA vector digested with HindIII and NotI gave a 4.2 kb 
band on the gel.  These restriction sites are within 60 base pairs of one another 
resulting a 4.2 kb band and a small band that was run off the gel.  The HindIII 
and NotI digestion of pCMV6-mTOR gives the mTOR band at 8.6 kb and the 
pCMV6 vector band at 4.7 kb.  Both undigested plasmids also show the 
relaxed, coiled and supercoiled states.  
B.  After dephosphorylation of phCMV2-HA vector, gel purfication was 
performed on pCMV6-mTOR and phCMV2-HA, both double digested with 
HindIII and NotI.  The double digestion created complementary sticky ends on 
both the vector and insert, facilitating their ligation.  The 4.7 phCMV6 vector 
was discarded, while the 8.6 mTOR insert and the 4.2 kb phCMV2-HA vector 
were collected from the gel.  
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The phCMV2-HA vector was digested with HindIII and NotI, sites which 
were conveniently present in the vector (Figure 12).   The resulting digested vector 
was then dephosphorylated to prevent reannealing of the vector onto itself, reducing 
the possibility of a looped section of plasmid DNA.  After dephosphorylation, the 4.2 
kb HindIIIphCMV2-HANotI vector was agarose gel purified alongside the 8633 bp 
HindIIImTORNotI insert.  The phCMV2-HA vector and mTOR inserts were excised from 
the gel, and after concentration determination, could be ligated because of 
complementary sticky ends. 
Next, the dephosphorylated Hind IIIphCMV2-HANot I vector was combined with 
a 3-fold molar excess of purified Hind IIImTORNot I insert.  The newly formed plasmid, 
named phCMV2-HAmTOR-WT contained a Kanamycin resistant gene which was 
used in colony selection and a HA tag which allowed for the tracking of transfected 
mTOR (Figure 13).  Transformation into DH5α cells immediately followed the 
ligation procedure.   
 
Characterization of the phCMV2-HAmTOR-WT Plasmid 
Nine robust colonies of DH5α cells transformed with the ligation reaction 
were selected from solid media for miniprep.  A miniprep was performed and a 1% 
agarose gel confirmed the presence or absence of the undigested plasmid.  Colonies 
which contained any amount of plasmid were subjected to a double enzyme digestion 
to determine the presence of a proper length fragment and the correct orientation of 
the mTOR insert into the vector (Figure 14).  The phCMV2-HAmTOR-WT double 

























Scheme showing vector map of phCMV2-HAmTOR-WT designed using 

















Double Restriction enzyme digestion of nine colonies of DH5α cells 
transformed with phCMV2-HAmTOR-WT.  Enzymes HindIII and EcoRV 
were chosen for the double digestion because HindIII is present only in the 
properly mutated mTOR insert.  The EcoRV restriction site serves as a 
way to check the orientation of the insert into the vector.  A 1.5 kb band 
along with an 11.3 kb band indicated a proper length, properly oriented 
plasmid.  Therefore, colonies 1 and 9, which have the expected bands at 
11.3 and 1.5 kb, were presumed to contain ligated plasmid and were 
further examined.  Colonies 2, 3 and, 8 were only linearized, indicating 
they did not contain one of the restriction sites.  The remaining colonies 
have other unexpected bands, indicating the ligation was not successful in 
those colonies.  All colonies except number 1 and 9 were discarded.   
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oriented phCMV2-HAmTOR-WT plasmid.  Only colonies one and nine contained the 
proper bands on the gel and colonies with bands of any other length were discarded.   
Purified phCMV2-HAmTOR-WT plasmid from colony nine was selected to 
transform DH5α cells.  It was determined by the gel that this colony contained a 
proper length and properly oriented plasmid.  This colony also had a higher 
concentration of plasmid than colony number one, the only other colony which had a 
properly oriented and proper length plasmid.  This additional transformation step 
provides extra assurance that the final plasmid is produced exactly as expected.  A 
maxiprep was performed on the transformed DH5α cells and purified phCMV2-
HAmTOR-WT was obtained.  Concentration and purity were determined with a 
spectrophotometer as well as on a 1% agarose gel.  (Figure 15).  DNA concentration 
was determined to be 400 ng/µl and DNA purity 1.8 (A260/280).  Again, restriction 
enzyme digestions were performed to confirm the presence of a proper length 
plasmid. Digestions with XmnI, BspEI, BamHI, EcoRI/NotI, HindIII/KpnI and 
Fsp/MfeI were performed, each reaction verifying the phCMV2-HAmTOR-WT 
plasmid (Figure 16).   
To further increase the assurance that the generated plasmid is what was 
desired, PCR primers were designed against phCMV2-HAmTOR-WT.   Two sets of 
PCR primers, each targeting a mutation site of the phCMV2-HAmTOR-WT plasmid 
were designed online at www.idtdna.com.  The lyophilized powder primers were 
purchased from Integrated DNA Technologies, Incorporated (Table 3).  After PCR 
the DNA fragments were run on a 2% agarose gel to confirm purity and proper 
length.  The remaining volume of PCR mixture was purified and sent for sequencing.   
10 kb
8 kb
9416 bp (150 ng)
23130 bp (300 ng)



























An agarose gel was used to check the concentration of the 12.8 kb 
phCMV2-HAmTOR-WT plasmid after maxiprep.  The 13.4 kb phCMV6-
XL4-mTOR was run as a reference, its concentration was previously 
established at 150 ng/µl.  phCMV2-HAmTOR-WT concentration was 
estimated at 400 ng/µl.  This estimate was verified by spectrophotometry.  






























Restriction enzyme digestions of phCMV2-HAmTOR-WT.  Digestions 
confirmed the proper orientation and size of plasmid.  XmnI cuts the 
plasmid only once and results in a linearized band at 12.8 kb.  BspEI cuts 
the plasmid at two sites and results in 6.0 and 6.8 kb bands.  BamHI 
digestion results in 4 cuts with bands at 5.5, 4.4, 1.9 and 1.0 kb.  The 
double digestion of EcoRI and NotI results in three bands at 7.3, 4.5 and 
1.0 kb.  The double digestion of HindIII and KpnI result in two bands, 
found at 6.9 and 5.9 kb.  FspI and MfeI double digestion result in 3 bands, 
found at 6.5, 4.9 and 1.3 kb.  The faint banding seen in the FspI/MfeI lane 
is likely undigested plasmid as a result of incomplete digestion in that 
reaction.  Each of the digestions confirms the presence of the phCMV2-




Concentration was estimated and the PCR reactions were sent to Cleveland Genomics 
for sequencing.  Sequencing confirmed the presence of the point mutations and thus 
the successful generation of the HA-tagged mTOR construct, phCMV2-HAmTOR-
WT.   
 
Aim 2:  Generate Mutated mTOR Plasmids by Site Directed 
Mutagenesis 
The newly generated phCMV2-HAmTOR-WT was further mutated to provide 
additional valuable molecular tools for the laboratory.  Using the same mutagenic 
procedures as described in the methods section, point mutations added additional 
restriction sites to the phCMV2-HAmTOR-WT construct and gave it different 
characteristics.   
Previously Jie Chen’s lab described a kinase dead mutant produced by 
mutating the Aspartic Acid (D) at position 2357 to a Glutamic acid (E)28.  This 
mutant gained an additional EcoRI site at that location, and was named phCMV2-
HAmTOR-D2357E (Table 4).  When analyzed on a gel, a restriction enzyme 
digestion of phCMV2-HAmTOR-D2357E with EcoRI would have 3 bands: 8.9, 3.0 
and, 1.0 kb.  Using New England Biolabs’ NebCutter, at www.neb.com, only 2 bands 
at 11.9 and 1.0 kb would be seen with a similar digestion of phCMV2-HAmTOR-
WT.   
In 2001 Chen’s lab described a different mTOR mutant, this time a PA 
deficient mutant that had its 2109 position Arginine mutated to an Alanine65.  This 












TABLE 4:   
 
Table indicates the mutations present in the three HAmTOR construct 
mutants.  Also indicates the sites added, the amino acid that was present 
prior to and after mutation, the mutation position and the stock concentration 
and purity of the construct.  For the purposes of this table, the phCMV2-
HAmTOR-WT is considered the parental plasmid, and therefore no mutations 
are listed.   
 
Plasmid phCMV2- phCMV2- phCMV2- phCMV2- 
 HAmTOR- HAmTOR- HAmTOR- HAmTOR- 
 WT D2357E R2109A S2035T 




Added N/A EcoRI NruI Afl3 
A.A. prior to 




Acid Alanine Threonine 
Mutation Position N/A 2357 2109 2035 
Stock 
Concentration 400 ng/µl 250 ng/µl 200 ng/µl 300 ng/µl  
Purity (260/280) 1.8 1.83 1.81 1.69 
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The parental phCMV2-HAmTOR-WT plasmid construct does not contain an NruI 
restriction site, therefore a restriction digestion of phCMV2-HAmTOR-WT with NruI 
results in a linearized plasmid(Table 4).   
The earliest described mTOR mutant came from Brown et. al., where the 
authors described the mutation of Serine at 2035 to a Threonine, creating a rapamycin 
resistant mutant37.  This mutant gained an additional AflIII restriction site and was 
named phCMV2-HAmTOR-S2035T (Table 4).  The phCMV2-HAmTOR-WT 
construct contains only three AflIII sites, and were seen at 6.0, 5.9 kb and, 882 bp.  
The phCMV2-HAmTOR-S2035T construct contains four sites which give observed 
bands at 6.0, 5.8, 1.0 kb and, 112 bp.   
The well planned mutation of these plasmids with the addition of a new 
restriction site provided the advantage of being able to easily identify the mutants.  A 
simple restriction enzyme digestion was all that was necessary to confirm that the 
successful mutation.  However, the mutants were subject to PCR to ensure the 
integrity of the plasmid.   
The three mutants described were prepared and sequenced in a fashion similar 
to the methods used to prepare the phCMV2-HAmTOR-WT plasmid.  Using 
phCMV2-HAmTOR-WT as the parental plasmid, PCR primers were carefully 
designed at www.idtdna.com to direct point mutations at the chosen sites (Table 2).  
These three separate point mutations conferred the desired additional restriction sites 
into the DNA.  The mutagenesis reactions were then used to transform XL-10 cells, 
and those colonies provided the material for a miniprep analysis.  After minipreps of 
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the three mutant plasmids, restriction enzyme digestions were designed to test for the 
presence of the new restriction sites, indicating a successful mutagenesis (Figure 17).   
The mutant plasmids were also subject to PCR and sequencing at Cleveland 
Genomics.  Cleveland Genomics sequencing revealed the successful point mutations 
of each of the plasmids, without any unexpected mutations in the DNA.  With the 
sequence of each of the three mutated plasmids confirmed, and after positively 
identifying the additional restriction sites on the restriction enzyme digestion gel we 
were able to conclude with certainty that our plasmids could be produced as planned.   
 
Aim 3:  Detect Protein Expression of Plasmids by Western Blotting; 
Probed with Anti-HA and Anti-mTOR. 
COS-7 cells were used for protein expression experiments because they are 
capable of expressing large quantities of protein and are easily cultured, even in sub-
optimal conditions.  The COS-7 cell line is from African green monkey kidney cells, 
and have a fibroblast morphology.  They are adherent to glass and plastic and retain 
complete permissiveness for lytic growth of the SV40 viral DNA, a circular DNA 
virus of Rhesus Monkey origin.  Each of the 4 plasmids generated in this thesis 
contain SV40.   
COS-7 cells were cultured in T-75 flasks and maintained in 90% DMEM, 
10% FBS.  For transfection, the cells were split into 6-well plates (Figure 18).  
Multiple products are available commercially for the transfection of adherent cells 




















































The digestion of the phCMV2-HAmTOR-R2109A construct, with its additional 
NruI restriction site gives two bands, 8.0, 4.8 kb as opposed to the WT plasmid 
which is linearized (12.8 kb) by the single cut of the EcorV enzyme.  The 
digestion of the phCMV2-HA-mTOR-D2357E construct shows the addition of an 
EcoRI site by the presence of the expected four band pattern shown: 7.2, 2.9, 
1.6 and, 0.9 kb.  The phCMV2-HAmTOR-WT plasmid was cut only three times, 
giving expected banding pattern of 10.2, 1.6 and, 0.9 kb.  The digestion of the 
phCMV2-HA-mTOR-S2035T plasmid gives the banding pattern 6.0, 4.5, 1.3, 0.9 
and, 0.1 kb due to the presence of an additional AflIII site.  The 113 bp band 
was run off the gel, but it is clear that the additional AflIII site is present due to 
the change from the phCMV2-HAmTOR-WT band of 1.4 kb to the mutant 
phCMV2-HAmTOR-S205T which shows a 1.3 kb band.  The phCMV2-
HAmTOR-WT plasmid banding shows the expected pattern of 6.0, 4.4, 1.4 and, 
0.9.  All banding patterns were predicted with NEBcutter 2.0 at www.neb.com.  
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Scheme outlining protocol for transfecting COS-7 cells using 
Lipofectamine and PLUS reagents to allow for the overexpression of HA-
tagged mTOR.  
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Lipofectamine-Plus combination.  The combination of Lipofectamine and Plus was 
chosen because the lab had previous success with those agents.   
Dose response experiments were carried out to establish the amount of each 
plasmid that was required for an effective transfection of the COS-7 cells.  For these 
experiments each of the four plasmids were transfected in different plates.  The 
phCMV2-HAmTOR-WT plate had wells with increasing amounts of plasmid as 
follows: 0.0, 0.5, 1.0, 1.5, 2.0 and, 3.0 µg.  Each of the mutant plasmids were also 
transfected in their own plate with an increasing amount of plasmid identical to the 
phCMV2-HAmTOR-WT plate.  The transfection reactions were allowed to precede 
for three hours after which time the cells were washed and incubated for another 48 
hours in DMEM + 10% FBS media.  Cell lysates were harvested using lysis buffer 
described in methods and a cell scraper to remove the adherent cells from the plastic 
culture wells.   
Additionally, time course experiments were performed to determine the 
optimal time for harvest of transfected COS-7 cells (Figure 19).  Transfections were 
performed with the phCMV2-HAmTOR-WT plasmid and compared with mock 
transfections.  Lysates were harvested at 0 hours (immediately after 3 hour 
transfection incubation), 15, 24, 48 and 72 hours.  The lysates obtained after a 72 
hour incubation had the highest concentration of total protein.  An increase in total 
protein has been interpreted as an indicator of cell growth.  While these two can not 
be absolutely conclusively linked, thymidine experiments in our lab have given 












COS-7 cells were transfected with either phCMV2-HAmTOR-WT or subject to 
a mock transfection.  The cell lysates were then harvested at 0, 15, 24, 48 or, 
72 hours.  The zero hour lysate was taken immediately after the 3 hour 
transfection incubation.  The black bars represent a mock transfection, the 
gray bars represent transfection with the phCMV2-HAmTOR-WT plasmid 
DNA.  An increase in total protein has been interpreted as an indicator of cell 
growth.  This interpretation has been verified in our laboratory through 
thymidine incorporation experiments.  Cell lysates taken at 72 hours had a 
moderate percentage of dead cells, and a noted morphology change.  Cell 
viability studies conducted by our lab have routinely shown a rapid decrease 
in cell viability 48 hours post-transfection.  For this reason, lysates for this 




There was a higher cell death rate in the cultures allowed to incubate for 72 
hours.  Also, by 72 hours post transfection there was a noted morphology change in 
some of the cells in the culture.  As a result, we determined that by 48 hours the cells 
had produced an adequate amount of protein for our experiments and had a consistent 
morphology.   
Protein concentration determination was carried out using a commercially 
available protein assay solution.  This concentration determination provided the 
necessary information to normalize the samples for SDS PAGE and Western Blot.  
After the samples were normalized to a standard quantity of protein, SDS-PAGE gels 
were run.  The embedded proteins were transferred to a PVDF membrane and a 
Western blot was performed (Figure 20).  Western blots consistently showed 
transfection with 2 µg of plasmid as optimal for maximum protein expression (Figure 
21).  Using 2 µg of plasmid DNA resulted in a four fold increase in protein 
expression over mock transfections.   
 
AIM 4:  Determine Enzyme Activity of Overexpression Plasmids 
using KLISA, Mass Spectrometry, or [32P] γ−ATP to detect 
phosphorylation of mTOR substrates. 
We used a commercially available mTOR kinase assay to determine kinase 
activity of the overexpressed HA-mTOR (Figure 22).  While there are a small number 
of articles which report some data while using a commercially available kit, this lab 
enjoyed little success with the product.  Various experimental conditions were used, 


































A.  Western Blots were probed with anti-mTOR and developed on X-ray 
film using the Kodak ECL method.  This experiment used cell lysates 
transfected with 2 µg of phCMV2-HAmTOR-D2357E plasmid DNA or a 
mock transfection.  Sonicates were taken and 600 ng total protein was 
loaded into each lane of the gel.  The PVDF was probed with the primary 
antibody Anti-HA and the secondary antibody, Anti-mouse.  In the mock 
transfection lane, a faint band representing endogenous mTOR can be 
observed at 289 kDa, noted by the red arrow.  The endogenous and 
exogenous mTOR is represented  by the darker band at 289 kDa in the 
lane with lysate from cells transfected with phCMV2-HAmTOR-D2357E.  
B.  Probing the blots with Anti-HA, we were able to visualize the 
exogenous mTOR only.  Thus in the mock transfected lane, there was no 
band because there was not any HA tag in that lysate.  In the 2 µg 
transfected lane, the band representing the transfected HA-mTOR can be 
visualized, again noted by the red arrow.  In subsequent experiments the 










































































Lysates were used for Western Blot analysis to determine protein expression 
of each of the constructs.  The films above depict the transfection of the 
noted amount and type of plasmid DNA.  The gels were probed with Anti-HA 
and Anti-mouse HRP.  The indicated 289 kDa band represents the HAmTOR 
present in each condition.  
Western Blots Probed with Anti-HA
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1.  Obtained COS-7 Lysates
3.  Incubated 50 ml mTOR 
lysate with 50 ml supplied 
Kinase Assay buffer and ATP in 
96 well plate
2.  Supplied mTOR substrate 
binds to solid support of 
Glutathione-coated 96 well 
plate
4.  Active mTOR was 
phosphorylated p70S6K at 
Thr389
5.  Phosphorylated substrate 
was detected with Anti-
p70S6K-T389 antibody 
followed by HRP-Antibody 
Conjugate and TMB substrate
6.  Absorbance was read at 
450 nm in Biotrak II Visable 
Plate Reader
Glutathione-Coated 96 well plate
mTOR ELISA Based Assay
FIGURE 22:
The commercially available mTOR activity Kit is an enzyme linked 
Immunosorbent assay (ELISA).  It relies on the phosphorylation of p70S6K-
GST fusion protein as its indicator of mTOR activity.  The phosphorylation is 
detected by Anti-p70S6K-T389 antibody followed by detection with HRP-
antibody conjugate and TMB substrate.  The relative activity of the mTOR 
was determined by the absorbance at 450 nm as determined by a Biotrak II 
Visable Plate Reader.  The manufacturer's protocol was followed for all 
steps of the assay.   
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reproducible data while using the kit.  A calibration was performed using the supplied 
mTOR standard and different types of water to ensure the pH of the samples did not 
effect the kit (Figure 23).  Calibrations revealed data that modeled the manufacturers 
standard curves, but with absorbance values that trended much lower than the 
manufacturers data.    
The data we obtained with the KLISA mTOR kit revealed a 2.6 fold increase 
in mTOR activity of the 1 µg W.T. plasmid transfected cells over mock transfections.  
Transfections with 2 µg of the W.T. plasmid revealed a five fold increase in mTOR 
activity.  However this data was not reliably reproducible and measured absorbances 
often varied widely (Figure 24).   
A literature review was conducted and revealed that other labs previously had 
difficulty with the commercially available mTOR kits.  Several kinase assay recipes 
were found, and a suitable one was modified for use.  The 2X Kim Kinase Buffer was 
used in combination with a Mass Spectrometer to obtain kinase activity data from the 
COS-7 cell lysates transfected with each of the 4 created plasmids.  COS-7 lysates 
were incubated with 2X Kim Kinase Buffer and prepared on a spectrometer protein 
chip.  The phosphorylated proteins should have been discernable from the non-
phosphorylated proteins by the 80 Dalton increase in molecular weight.  
The cell lysate and Kinase assay buffer were incubated with active and 
inactive versions of p70S6 Kinase as well as 4E-BP1.  As discussed earlier, both are 
known downstream phosphorylation targets of mTOR.  A calibration with Bovine 
Serum Albumin (BSA) was performed to determine the sensitivity of such an 
experiment (Figure 25).  Unfortunately it was soon suspected that the amount of  
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mTOR KLISA kit calibrations.  Each of graphs represents a calibration of the 
KLISA kit, using different types of water with the mTOR standard supplied with 
the kit.  A dilution series was made up using 0.0, 0.5, 1.0, 2.5, 5.0, 10.0, 25.0 
and 50.0 ml of mTOR standard, the specified type of water was used to bring 
the total reaction mixture to 50 ml.  The Y-axis lists measured absorbance, the 
X-axis represents the amount (in ml) of water present in the sample. Each of 
the graphs was fit with a polynomial regression line with the lowest R2 value of 
0.97.  
A.  Water from distilled water tap on the lab bench.  
B. Molecular Biology Grade, Ultrapure RNA'se free water supplied from USB.  
C. RNA'se free water supplied from Qiagen.  




Lysate # COS7 Transfection Abs 450 Units ng/rxn U/ng
1 Mock 0.0 0.161 12.636 4.203 2.988
2 1.0 µg WT 0.165 16.273 4.229 7.741


















Kinase activity as determined by mTOR KLISA kit.  
A.  The graph shows µg of phCMV2-HAmTOR-WT used for the transfection 
on the X-axis.  The Y-axis is the units of mTOR activity.  Units of mTOR 
activity were defined arbitrarily, by comparing the experimental values to 
those obtained from the supplied mTOR standard.  
B.  The chart defines the paramaters used to construct the graph.  Lysate 
number was assigned for tracking purposes.  COS-7 transfection details the 
amount of plasmid DNA used to transfect the condition.  Abs 450 is the raw 
data obtained from the visable plate reader.  Units is a relative measurement 
of mTOR activity compared to a µl quantity of mTOR standard supplied with 
the kit.  This relative number takes into account the amount of DNA in each 
sample and the corresponding amount of mTOR actvity.  The standard curve 
generated an equation of Y = 0.0011x + 0.1471.  This equation was used to 
obtain the Units value for the chart.  The amount of protein per condition is 
listed as ng/rxn.  The value of Units/nanogram is listed last and shows the 
mTOR activity per nanogram of total protien.  
µg transfected phCMV2-HAmTOR-WT 
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FIGURE 25:
A Bovine Serum Albumin (BSA) calibration was performed to insure the 
mass spectrometer was functioning properly and could detect proteins at 
different concentrations.  BSA, a 66 kDa protein could be easily detected 
above the 10 ng quantity, but detection below that quantity was poor.  The 
chart shows the peaks seen when a protein chip was run with the quantity 





glycerol in the kinase mixture was too great, inhibiting the detection of the small 
quantities of protein.  The chip which the kinase assay was run on often did not dry 
out enough for the mass spectrometer to read it.  Therefore, the chips often sat in a 
37°C oven overnight or in some cases, over the weekend in an attempt to dry them.   
After the chips were dried, the spectrometer revealed no peaks that could be 
reasonably linked to this experiment (Figure 26).  Therefore, no conclusive results 
could be obtained.  The expected shift could not be visualized, and in some cases, no 
protein could be detected.  Various adjustments to Kim’s Kinase buffer were unable 
alleviate the difficulties encountered with this method of kinase assay.   
A third kinase assay was developed using radiolabeled [32P]γ−ATP (Figure 
27).  This assay was adapted from Kim et. al. and designed to avoid some of the 
difficulties the previous assays posed10.  COS-7 cell lysates were taken as described 
in Methods, and an immunoprecipitation was performed with HA-agarose beads in an 
effort to concentrate the transfected mTOR.  This assay used the 4X Kim Kinase 
Buffer and the immunoprecipitation reactions were incubated with either p70 S6 
Kinase or 4E-BP1 protein.  Experiments with p70 S6 Kinase (T412E), an active 
kinase, revealed a large amount of autophosphorylation.   
The ability of p70 S6K to autophosphorylate covered the phosphorylation that 
was expected by mTOR (Figure 28).  The kinase reaction using 4E-BP1 enjoyed 
more success, in part because 4E-BP1 does not have any autophosphorylation 
abilities (Figure 29).  This assay shows the ability of mTOR to incorporate 
[32P]γ−ATP into 4E-BP1.  Lysates from COS-7 cells were used for the 4E-BP1 kinase 







The mass spectrometry kinase reaction did not reveal any discernable 
peaks.  
A.  Kinase reaction with no 4E-BP1, to get a baseline.  
B. 4E-BP1 and [32P]γ -ATP incubated with lysate from mock transfection.  
C. 4E-BP1 and [32P]γ -ATP incubated with lysate from transfection with 
phCMV2-HAmTOR-WT.  
D. 4E-BP1 and [32P]γ -ATP incubated with lysate from transfection with 
phCMV2-HAmTOR-D2357E.  
E.  4E-BP1 and [32P]γ -ATP incubated with mTOR standard that was 
supplied with commercially available mTOR kinase assay kit.  














An mTOR kinase assay was developed using [32P]γ-ATP to detect 
phosphorylation of the known substrates, p70 S6K and 4E-EBP.  Lysates 
of COS-7 cells transfected with the HA-mTOR plasmids were incubated 
with 5 µci of [32P]γ -ATP and one of the substrates.  The kinase reaction 
was incubated for 20 minutes and then run on an SDS-PAGE gel.  The 
proteins in the gel were transfered to a PVDF membrane which was then 




















































 [32P]γ-ATP Kinase Assay
FIGURE 28:
X-ray film shows kinase assay using [32P]γ-ATP.  COS-7 cells were 
transfected as indicated and lysates used in kinase assay.  This assay 
used p70 S6 Kinase (T412E) active, as the substrate.  mTOR is known to 
phosphorylate the 48.7 kDA downstream target, p70 S6k.  We were 
expecting mTOR to encorporate the [32P]γ-ATP into the p70 S6K and the 
degree of phosphorylation would be detected by the intensity of the band 
on the film. However in this experiment, all the lanes, including the mock 
transfection and the lane with no lysate showed phosphorylation. We now 
hypothesize that the active p70 S6K autophosphorylated and covered any 
mTOR phosphorylation of the kinase.  When the experiment was repeated 
with heat denatured p70 S6K to render the kinase inactive, no 



























 [32P]γ-ATP Kinase Assay
FIGURE 29:
X-ray film showing kinase assay using [32P]γ-ATP.  This assay used 
protein 4E-BP1 as the substrate.  mTOR is known to phosphorylate the 
21 kDA downstream target, 4E-BP1.  This protein is not able to 
autophosphorylate and provided a more accurate picture of the kinase 
activity of mTOR.  The first lane is lysate taken from COS-7 cells 
transfected with phCMV2-HAmTOR-WT.  The second lane is lysate taken 
from a mock transfection.  The mock transfection shows some mTOR 




PVDF membranes.  These membranes with the proteins, and incorporated 
[32P]γ−ATP were then exposed to X-ray film (Figure 30).  Once the film was 
developed, ImageGauge V.4.0 software was used to quantify the band strength of the 
phosphorylated protein (Figure 31).   
The ImageGuage software revealed a 13 fold increase in phosphorylation of 
4E-BP1 with the phCMV2-HAmTOR-WT plasmid over a mock transfection.  
Additionally the Kinase Dead mutant, phCMV2-HAmTOR-D2357E had a 4 fold 
increase in phosphorylation.  The two other plasmids, phCMV2-HAmTOR-R2109A 
and phCMV2-HAmTOR-S2035T showed still larger increases in phosphorylation of 
4E-BP1 when overexpressed in COS-7 cells.   
This third kinase assay had the most success of the three assays.  
Phosphorylation of the two substrates could be detected, but phosphorylation levels 
varied.  Several changes were made in the technique used to incubate the kinase 
mixture, and the amount of [32P]γ−ATP used in the reaction was varied.  The 
difficulty of obtaining mTOR kinase data does not come completely as a surprise 
however.   
Researchers hypothesize that because of the large mulitmeric structure of 
mTOR, that the processing of mTOR for kinase assay can interrupt these 
interactions10.  The roles that these additional proteins play is largely unknown, but 
suspected to mediate kinase activity and mTOR function.  Ongoing studies to 
establish more firmly the in vivo protein to protein interactions is essential to the 

































The kinase reaction using 4E-BP1 and [32P]γ-ATP was analyzed using Fuji 
ImageGauge V.4.0.  A reference area was obtained for each band and is 
noted as a black oval on the gel.  The relative density of this oval was 
measured with the software.  An oval of the same area, in red, was then 
used to measure the relative density of the 21 kDa 4E-BP1 
phosphorylated band.  The reference density was then subtracted from 
the band density to obtain a relative density indicating the amount of 
































Relative Density for each sample from the previous figure.  The mTOR 
standard was supplied with the mTOR KLISA kit and was run to determine 
if the standard contained any active mTOR.  Its relative value should be 
considered alone and not compared to that of the other samples.  
Transfection with 2 µg of phCMV2-HAmTOR-WT yielded a relative density 
of 2.63.  Transfection with D2357E gave a relative density of 0.79.  
Transfection with R2019A gave a relative density of 4.43.  Transfection 
with S2035T gave a relative density of 8.00.  A mock transfection yielded a 






AIM 5:  Investigate the effects of mTOR Transfection on Gene 
Expression and Sub-cellular Localization 
Gene Expression 
Real Time PCR is a tool which has a high sensitivity to small amounts of 
DNA and is generally more accurate than traditional PCR.  This tool allowed 
investigation into the molecular workings of the cell.  Using the computer generated 
Ct values the gene fold of a mock transfection could be compared to that of cells 
transfected with plasmid DNA.  Gene fold is a relative measurement of the greater 
number of copies cDNA are produced during a PCR reaction.  
RT-PCR relies on the fluorescence of a probe attached to a primer designed 
against a gene of interest (Figure 32).  Taqman gene expression probes were obtained 
for these experiments from Applied Biosystems, Foster CA.  These probes were 
designed against the sequence of interest: mTOR, S6K and PLD2.  The probe is 
bound just downstream of the primers, near the target sequence.  When the 
polymerase reaches the 5’ end of the probe, the fluorophore, attached at the 5’ end of 
the probe is released.  Once the flourophore is released, it is free of the inhibitory 
effects of the 3’ quencher molecule.  It is this separation that causes the fluorescence 
which is subsequently detected by the Real Time PCR machine.  The intensity of 
fluorescence is increased as the number of DNA template increases, and more 
flourophore’s are released.  
Lysate from COS-7 cells transfected with plasmid DNA were obtained and 
RNA was extracted from the lysates with a Qiagen RNeasy Kit.  RNA was quantified  
Detection
FIGURE 32:
Scheme outlines Real Time PCR chemistry using the Taqman probes.  
Taqman DNA polymerase moves in a 5' direction toward the Taqman 
probe.  The exonuclease activity of the polymerase causes the release of 
the flourescent dye into the solution.  With the release of the dye the 
quencher can no longer mask the signal of the flouophore.  The increase 
in flourescence is detected during the exponential phase of the PCR 
reaction.  Obtaining data at the exponential phase of the PCR  reaction is 




against an RNA standard using Molecular Probe’s Ribogreen RNA Quantitation Kit.  
An equal amount of RNA from each condition was reverse transcribed to cDNA.  
After cDNA was obtained, RT-PCR could be carried out.  For this thesis each of the 
transfection conditions from which the cDNA was obtained were incubated with the 
mTOR PCR probe.  This allowed the detection of mTOR in all the transfection 
conditions (Figure 33). 
Using the Ct value which was calculated by the PCR computer, the gene fold 
could be calculated for each of the experimental conditions.  The fluorescence of the 
mTOR probe is compared against the fluorescence of a housekeeping gene, in this 
case glucuronidase.  This ∆Ct value was then compared against the mock transfection 
to normalize the data.  This ∆∆Ct value is then used in the equation y=2(-∆∆Ct) where y 
is the gene fold97.  This calculation gives a relative value of the amount of mTOR 
cDNA present in the sample.   
Our data shows that transfection with the mTOR plasmid DNA constructs 
does in fact significantly increase the gene fold of a sample (Figure 34).  We detected 
a 170 fold increase in mTOR gene expression using our phCMV2-HAmTOR-WT 
plasmid.  Additionally, the kinase dead phCMV2-HAmTOR-D3457E plasmid 
showed a 160 fold increase in gene expression.  The Myc-PLD2 plasmid, when 
lysates were probed for mTOR gene expression, showed only negligible change.  
 
Immunoflourescence Microscopy 
Immunoflourescense images were obtained to visualize the localization of the 
























Real Time PCR was used to determine the increase in gene fold after 
transfection with a DNA plasmid.  The graph shows a typical readout from the 
RT-PCR machine.  The purple horizontal line represents the Ct value, 
calculated by the RT-PCR machine.  A smaller Ct value represents a higher 
cDNA expression, and thus larger gene fold.  All conditions were probed with 
the mTOR probe.  Thus the relative amount of mTOR in each sample was 
examined.  The lysates transfected with phCMV2-HAmTOR-D2357E, 
phCMV2-HAmTOR-WT and, pCMV6-XL4-mTOR each have a relatively high 
mTOR gene fold, as would be expected.  The mock transfection and myc 
PLD2 have lower mTOR levels as they are only expressing basal mTOR.  
The no DNA template control is run to ensure the validity of the data and 
shows no amplification until the end of the PCR reaction.  
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Transfection Condition Mock T.F. HAmTOR WT pCMV6-XL4-mTOR phCMV2-HAmTOR-D2357E Myc-PLD2
mTOR(FAM) 22.01 14.49 18.09 14.12 22
Gluc (TexRed) 23.07 22.96 26.87 22.5 23.66
∆Ct -1.06 -8.47 -8.78 -8.38 -1.66
∆∆CT 0 -7.41 -7.72 -7.32 -0.6
2^(-∆∆CT) "Gene Fold" 1.0 170.1 210.8 159.8 1.5
GENE FOLD ANALYSIS
FIGURE 34:
Using the ∆∆Ct value, gene fold for each of the transfection conditions can 
be calculated.  The ∆Ct value is calculated by subtracting the Ct value of 
the gene of  in terest  f rom the Ct value of  a housekeeping gene,  
glucuronidase.  This ∆Ct value is then subtracted from the mock 
transfection to normalize the samples to obtain a ∆∆Ct value.  Finally the 
∆∆Ct value is used in the equation 2−∆∆Ct to obtain gene fold.  This data 
shows a 170 times increase of the mTOR gene in the phCMV2-HAmTOR-
WT transfected lysates compared to the mock transfection.  The pCMV6-
XL4-mTOR plasmid showed a 210 t imes increase in mTOR gene 
expression.  Similarly phCMV2-HAmTOR-D2357E showed a 160 times 
increase.  The lyastes from Myc-PLD2 transfected cells showed no 






COS-7 Cells transfected with phCMV2-HA-mTOR-WT (A and B) or a Mock 
Transfection (C and D).  The polymerized Actin in the cell is stained red with 
Phalloidin TRITC dye containing a Rhodamine tag.  The DNA is stained 
blue by a DAPI dye.  The flourescent green color is the transfected mTOR, 
tagged by the anti-HA FITC antibody conjugate.  The mTOR has a 
perinuclear distribution, and none was observed in the nucleus or around 




cells with phCMV2-HAmTOR-WT or a mock transfection.  The images show indeed 
transfected mTOR was able to enter the cells as endogenous mTOR is not seen.   
The polymerized actin, a structural protein, was dyed red with Phalloidin-
TRITC containing a Rhodamine tag.  The DNA was stained blue with a DAPI dye in 
order to visualize the nucleus of the cell.  The transfected HA-mTOR fluoresced 
green after it was incubated with conjugate an anti-HA FITC antibody.  No mTOR is 
seen within the nucleus as this would appear as a yellow or orange color on the 
images.   
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V.  CONCLUSIONS 
 
1. Previous studies have lacked a reliable means of overexpressing mTOR in 
mammalian cells.  
2. We have developed four phCMV2-HA-tagged mTOR plasmids: Wild Type, 
D2357E (Kinase Dead), R2109A (PA Binding Deficient) and S2035T 
(Rapamycin Resistant).  Each one has 12,832 base pairs, and all were verified 
by restriction enzyme digestions and direct sequencing.   
3. Plasmid DNA was overexpressed in COS-7 cells and the mTOR protein of 
289 kDa was found in Western Blots developed with anti-HA or anti-mTOR.  
The overexpressed protein showed a four fold increase over the endogenous 
mTOR.   
4. Kinase activity of the overexpressed protein was measured by 
phosphorylation of 4E-BP1 and S6K.  Lysates of cells transfected with 
phCMV2-HAmTOR-WT had a 13 fold increase in 4E-BP1 phosphorylation 
over the mock transfected cells.  The Kinase Dead mutant had only a 4 fold 
increase in kinase activity over the mock.  The R2109A and S2035T mutants 
had a 22 fold and 40 fold increase, respectively, over the mock transfections.   
5. mTOR gene expression was elevated over that of the mock transfections as 
detected by QRT-PCR.  Cells transfected with the phCMV2-HAmTOR-WT 
plasmid DNA had a 170 fold increase in mTOR gene expression over mock 
transfected cells.  The Kinase Dead mutant showed a similar 160 fold 
increase.  However, gene expression of PLD2 was not effected by the over 
expression of mTOR.   
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6. Subcellular localization by immunoflourescence indicated that mTOR is 
concentrated in perinuclear space and none was observed in the nucleus or 
near the plasma membrane .  We hypothesize that mTOR is concentrated in 
endosomal formations near the nucleus for use in translation regulation.   
7. This study provides important molecular biology tools for this lab’s continued 
investigation into the crosstalk between mTOR, S6K, PLD1 and PLD2.   
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VI.   DISCUSSION 
 
 
The results presented in this thesis fall within the overall study of four signal 
transduction molecules: mTOR, S6K, PLD1 and PLD2 and their interaction in a 
living cell.  The work to generate and characterize an HA-tagged mTOR construct has 
provided the lab with another method of investigating these important pathways.  
Previously studies have focused on work with siRNA technology and a new 
electroporation method to deliver DNA to the cell nucleus.  Tabatabaian, M.S., was 
successful in using these technologies to show that cells transfected with si-mTOR 
and si-S6k often had a PLD2 gene expression of several hundred times the basal rate.  
The new HA-tagged mTOR plasmid constructs allow for mTOR overexpression and 
the subsequent study of the effect of mTOR overexpression on S6K and PLD which 
was lacking in the previous study.   
The first two aims of this thesis were accomplished through the preparation of 
the HA-tagged plasmid, phCMV2-HA-mTOR and subsequent point mutations of the 
parental plasmid to obtain the mutated HA-tagged plasmids.  These four plasmids 
were characterized through restriction enzyme digestions and were sequenced by 
Cleveland Genomics.  They were transfected into mammalian cells with a high 
efficiency, and cell lysates from those tranfections supplied the raw material for the 
remainder of the experiments in this thesis.     
Protein expression of the HA-tagged mTOR was accomplished by transfecting 
the mTOR plasmids into mammalian COS-7 cells.  COS-7 cells were chosen because 
of their ease of transfection and ability to produce large amounts of protein.  Lysates 
were obtained, SDS-PAGE gels run and the proteins were transferred to a PVDF 
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membrane.  Western Blotting with anti-HA and anti-mTOR was able to detect the 
expression of mTOR.  We concluded that 2 µg of plasmid DNA was adequate to 
transfect one well of a six well plate of COS-7 cells at 70% confluency.  Using a 
greater quantity of plasmid for transfection seemed to negatively affect the cells, 
resulting in more cell death and greater morphology changes before the lysates were 
harvested at 48 hours after transfection.   
During protein expression experiments, we experienced a variability in the 
amount of total protein that each six well produced.  This variability may have been 
due to the cell harvesting techniques, effectiveness of the lysis buffer or, simply a 
result of the variability that is inevitably expected in dynamic biological systems.   To 
prevent this variability and to increase the confidence in the protein differences 
between samples, larger wells or multiple wells for each condition should be used, 
and the lysates combined.  This provides for a larger amount of protein to work with 
and reduces the variability associated with any live cell experiment.   
Various mTOR kinase assays were attempted to show the activity of the WT 
plasmid compared to the mutated plasmids.  We were able to show through the 
phosphorylation of 4E-BP1, that the overexpressed plasmids increased the 
phosphorylation of the downstream target compared to a mock transfected lysate.  
The data shows a 13 fold increase in 4E-BP1 phosphorylation with phCMV2-
HAmTOR-WT transfected lysates versus the mock transfected lysates.  Additionally, 
the Kinase Dead plasmid, phCMV2-HA-mTOR-D2357E, had only a four fold 
increase in phosphorylation over the mock transfections.  This is directly in line with 
the approximately 60% reduction in kinase activity published by Park, et. al.41.   
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mTOR kinase assay data is scarce in the published literature, but those authors 
that do publish results often report variability in kinase activity, similar to what we 
experienced. It is thought that the variability is a result of the many protein to protein 
interactions that regulate the activity of mTOR10.  The loss of one or more of these 
associated proteins during the lysate isolation process may effect the ability of mTOR 
to remain as an active kinase for an in vitro assay.    
There are several pieces of evidence that support the missing protein theory.  
The first is that mTOR contains HEAT repeats, described in the literature review of 
this thesis.  These HEAT repeats are known to be protein to protein interaction 
domains.  These HEAT domains may form an extended superhelical structure, 
creating multiple large interfaces for proteins to interact98.  Second, in gel filtration 
chromatography, mTOR migrates at a disproportionately large apparent molecular 
weight of 1.5 to 2.0 mDa10.  While this phenomenon was not observed during our 
experiments, this data suggests a close association between mTOR and other protein.   
mTOR is known to be sensitive to several standard lysate treatment solutions.  
Non-ionic detergents such as Triton X-100 and NP40 should not be used because they 
inactivate mTOR99.  Cell lysis buffers for this thesis included Tween-20, which does 
not cause the same dissociation as the non-ionic detergents.  Also, mTOR is sensitive 
to phosphate containing buffers and therefore PBS should not be used99.  This 
sensitivity was not understood until just a few years ago, and much of the literature 
published before 2003 report using PBS in their kinase assays83.  mTOR also requires 
Mn2+ for activity, which was included in our kinase assay buffers.   
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The [32P]γ−ATP kinase assay was the only assay that we used that produced 
repeatable mTOR kinase activity data.  We showed the ability of mTOR to 
phosphorylate 4E-BP1 and analyzed the data using Fuji ImageGauge V.4.0.  Our 
kinase dead mutant, phCMV2-HAmTOR-D2357E, showed less than half the activity 
of the phCMV2-HAmTOR-WT plasmid.  The two other mutants, R2109A and 
S2035T showed a higher kinase activity than the WT plasmid.  The [32P]γ−ATP 
kinase assay using p70 S6K as a substrate did not provide the same results.  We 
hypothesize that the autophosphorlyation capabilities of p70 S6K inhibited our ability 
to discern what effects mTOR had on this downstream molecule.  Interestingly, when 
p70 S6K was heat inactivated in an effort to prohibit its autophosphorylation 
capabilities, no mTOR kinase activity was observed.   
Futher studies on the intricate interactions between mTOR and its associated 
proteins are needed in order to study kinase activity.  Too little is known even about 
the structure of mTOR to assert that each of its domains is fully understood.  These 
domains play an important role in protein to protein interactions which may modify 
the activity of mTOR.  Studies need to focus on associated mTOR proteins as 
important modulators of mTOR activity such that a reliable kinase activity assay can 
be developed without concern of loss of activity due to disruption of these proteins.    
Real time PCR has proven itself as a reliable tool for investigating gene 
expression at the earliest detectable time in the cell; cDNA expression.  Our 
experiments showed that each of the HA-tagged mTOR plasmids were able to 
increase the amount of mTOR cDNA being transcribed in the transfected cells.   
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Gene folds of phCMV2-HAmTOR-WT transfected cells increased 170 fold 
over that of the mock transfected cells.  Similarly the Kinase Dead D2357E plasmid 
had a gene fold of 160 times the mock.  For this experiment we expected a similar 
increase in gene expression with each of the plasmids.  Although the D2357E mutant 
has a reduced kinase activity, the cDNA copies of the gene are still made at an 
increased rate over the mock transfections.  The pCMV6-XL4-mTOR plasmid 
obtained from OriGene had a gene fold increase of 210 times the mock transfection.  
When a Myc-PLD2 plasmid was used to overexpress PLD2, no change in mTOR 
gene expression was detected.   
Our data showed no significant change in PLD1, PLD2 or S6K expression 
with the overexpression of mTOR using the HA-tagged plasmids.  This lab has 
previously shown that mRNA expression of PLD2, mTOR and S6K are coordinately 
regulated.  In her thesis, Tabatabaian, M.S., showed that transfecting dHL-60 cells 
with si-mTOR and si-S6k caused PLD 2 gene expression to rise dramatically96.  The 
data that we have does not show the opposite to be true.  The overexpression of 
mTOR using HA-tagged mTOR constructs does not seem to increase PLD2 gene 
expression.  However, more studies need to be completed to confirm this hypothesis.  
Studies should include rapamycin and wortmanin, known inhibitors of mTOR.  
Additionally experiments adding growth factors to attempt to upregulate mTOR 
should be attempted.   
Finally, fluorescence images were obtained of COS-7 cells transfected with 
HA-mTOR.  These images provided confirmation that mTOR is a cytosolic protein, 
localized very near the nucleus.  These findings agree with Liu et al. who published 
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findings stating that mTOR had unusual endoplasmic reticulum and Golgi apparatus 
targeting sequences in its HEAT domain100.  The location of the transfected mTOR 
may be due to the fact that mTOR is shuttled in and out of the nucleus in order to 
interact with S6K101.  However, no mTOR was observed within the nucleus.  This 
may be explained by the fact that there was no mTOR in the nucleus, the anti-HA 
antibody was unable to penetrate the nucleus, or the mTOR was not yet transported to 
the nucleus.  Experiments to follow the movement of mTOR throughout the life cycle 
of the cell would provide additional evidence to support the theory that mTOR is 
shuttled to and from the nucleus.   
The importance of understanding the interactions between these molecules 
can not be underestimated.  In this thesis we have established that mTOR plays the 
roles of both the receptor of cellular signals and as an initiator of cellular pathways.  
An understanding of mTOR’s pathways and, those effected by the crosstalk between 




VII. SIGNIFICANCE OF THIS STUDY 
 
 
mTOR is thought to be a master regulator of the cell.  Understanding how this 
protein kinase is regulated in healthy cells and how it becomes dysregulated in 
diseased cells is important to our understanding of many different diseases.  This 
study produced four HA-tagged mTOR expression plasmids that were effectively 
transfected in mammalian cells.  These constructs provide the lab with the molecular 
tools to study the crosstalk between mTOR and various other molecules.  The 
plasmids are available in purified form for the lab and glycerol DH5α stocks exist so 
the plasmid can be easily replenished.  Each of these plasmids went through extensive 
testing including restriction enzyme digestions and sequencing by a third party.   
Western Blotting showed that the HA-mTOR plasmid DNA could be 
overexpressed in mammalian cells, and detected with both anti-mTOR and anti-HA 
antibodies.  Kinase assays showed the transfected mTOR was active, and the kinase 
dead mutant showed an expectedly decreased phosphorylation ability.  Cells 
transfected with these plasmids also showed an increase in mTOR gene expression as 
detected by Real-Time PCR.  The HA-mTOR protein was visualized by 
immunoflourescence microscopy, which confirmed its perinuclear location.   
The results of this study complete the next step in the investigation between 
the crosstalk of these signaling molecules.  Gene expression studies should be 
continued to further verify the effect of mTOR overexpression on PLD1, PLD2 and 
S6K.   
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